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CD69 is induced after activation of leukocytes at inflammatory sites. Mice lacking CD69 develop 
exacerbated forms of inflammatory diseases, which are largely mediated by misbalanced responses of 
T helper (Th) 17 cells and regulatory T cells (Tregs), indicating that CD69 modulates Th17 
differentiation and plays a role in regulatory T cell function. However, the pathophysiological role of 
CD69 in fibrotic diseases remains largely unknown. 
 
Renal patients subjected to peritoneal dialysis (PD) develop progressive peritoneal fibrosis, which 
may lead to technique failure. Herein, we observed that infiltrating T lymphocytes of PD patients 
expressed high levels of CD69.  
 
Thus, we explored the role of CD69 in fibro-proliferative responses by analyzing a model of 
peritoneal fibrosis induced by dialysis fluid exposure in WT and CD69-deficient mice. CD69–/– mice 
showed enhanced peritoneal thickness and myofibroblasts accumulation as well as higher incidence of 
mesothelial to mesenchymal transition (MMT). In parallel, CD69–/– mice showed exacerbated 
inflammatory infiltrates, a marked increase of Th17 cells and IL-17 cytokine and reduction of Tregs. 
Transplantation of a mixture of bone marrows from CD69–/– and Rag2–/– mice into WT recipients 
reproduced the severity of the disease upon PD fluid exposure, demonstrating that CD69 exerts its 
function within the lymphocyte compartment. Blockade of IL-17 in CD69–/– mice reduced Th17 
response and inflammatory infiltrates and resulted in decreased peritoneal fibrosis induced by PD 
fluid.  Conversely, blockade of CD69 in WT mice mimicked the exacerbated response of CD69–/– 
mice to PD fluid exposure.  
 
Our findings indicate that CD69 modulates Th17-mediated inflammatory responses in the peritoneal 
cavity and negatively regulates peritoneal fibrosis induced by dialysis fluid exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  |	  P a g e 	  	   20	  
El receptor CD69 se induce tras la activación leucocitaria en los infiltrados inflamatorios.  Los ratones 
deficientes en CD69 desarrollan formas exacerbadas de enfermedades inflamatorias que están 
mediadas por una respuesta desbalanceada entre linfocitos T “helper” Th17 y células T reguladora 
(Tregs), lo que indica que CD69 modula la diferenciación de Th17 y que juega un papel en la función 
de las células Tregs. Sin embargo, el papel fisio-patológico de CD69 en enfermedades fibróticas es 
desconocido.  
 
Los pacientes renales sometidos a diálisis peritoneal (DP) desarrollan fibrosis peritoneal progresiva, la 
cual puede dar lugar al fallo de la técnica. En este estudio, hemos observado altos niveles de 
expresión de CD69 en los linfocitos infiltrantes de los pacientes en DP. 
 
Por lo tanto, decidimos explorar el papel de CD69 en la respuesta fibroproliferativa mediante el 
análisis de un modelo de fibrosis peritoneal inducido por líquidos de diálisis en ratones silvestres y en 
ratones deficientes para CD69. Los ratones CD69–/– mostraron un mayor engrosamiento peritoneal y 
una mayor acumulación de miofibroblastos, así como una mayor incidencia de transición mesotelio 
mesenquimal (TMM). En paralelo, los ratones CD69–/– mostraron infiltrados inflamatorios 
exacerbados, un marcado aumento de células Th17 y de la citoquina IL-17 y una reducción de células 
Tregs. El trasplante de una mezcla de medulas óseas procedentes de ratones CD69–/– y Rag2–/– en 
ratones silvestres reprodujo la severidad de la enfermedad inducida por la exposición al líquido de 
DP, demostrando asi que CD69 ejerce su función en el compartimento de linfocitos. El bloqueo de IL-
17 en ratones CD69–/– redujo la respuesta Th17 y el infiltrado inflamatorio y dio lugar a una reducción 
de la fibrosis inducida por  el líquido de DP.  Por otro lado, el bloqueo de CD69 en ratones silvestres 
mimetizó la respuesta exacerbada a la exposición del liquido de diálisis de los ratones CD69–/–.   
 
Nuestros resultados indican que CD69 modula la respuesta inflamatoria mediada por Th17 en la 
cavidad peritoneal y regula negativamente la fibrosis peritoneal inducida por la exposición a liquido 
de diálisis. 
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1. Early leukocyte activation antigen CD69 	  
1.1. Genomic organization and chromosomal localization of the CD69-encoding gene 
 
The cloning of the human early lymphocyte activation antigen CD69 was performed for the first time 
in 1993 by Lopez-Cabrera1. CD69 is the first activated cell surface receptor on leukocytes2-4 and is a 
C-type lectin, disulfide-linked homo-dimer (24 kDa) type II protein, as well as a member of the 
natural killer (NK) receptor family. Its genes are located in a genomic region known as the NK gene 
cluster on mouse chromosome 6 and human chromosome 121, 4-6 (Figure 1). The genetic and 
molecular characteristics of mouse CD69 are very similar to its human homologue6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Genomic localization of CD69 gene in human and mouse. Promoter region is highlighted (González-
Amaro et al, 2013). 
 
 
1.2. CD69 expression 
 
CD69 is detected on small subsets of T and B cells in peripheral lymphoid tissues from healthy 
subjects6-8 but is undetectable on peripheral blood lymphocytes. Furthermore, CD69 is persistently 
expressed by platelets, mature thymocytes, bone marrow and lymphoid precursors and generally in 
leukocytes infiltrates of various chronic inflammatory diseases9, 10, suggesting that inflammatory 
cytokines might be involved in CD69 expression. The genomic organization, promoters regions and 
transcriptional activity of the human CD69 gene have been described1, 11, 12.  
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The transcription of CD69 gene appears to be tightly regulated in vivo, as it is almost exclusively 
expressed at sites where inflammation takes place, suggesting that inflammatory cytokines might 
participate in the control of the CD69 expression. The sequence upstream from the gene functions as a 
phorbol myristate acetate (PMA)-inducible promoter element. It has been confirmed by the 
observation that the expression of CD69-encoding mRNA in leukocytes is induced by in vitro 
treatment with a wide range of stimuli, including PMA1. Specifically, the CD69 promoter region 
contains binding sites for transcription factors such as nuclear factor (NF)-κB, activator protein (AP)-
1 and erythroblast transformation-specific related gene (ERG)-1 (Figure 1). In the case of the NF-κB 
binding site it has been shown that it also mediates the tumor necrosis factor (TNF)-α-induced 
expression of CD69. This could explain the expression of CD69 in sites of chronic inflammation, 
characterised by abundant TNF-α expression11. Similarly, ERG-1, whose expression is induced by 
various agents, including phorbol esters, has been implicated in the activation of lymphocytes B and 
T13.  
 
1.3. Functional characteristics of hematopoietic cell lineages in CD69 deficient mice 
 
To investigate the physiological relevance of CD69, the first CD69-deficient (CD69-/-) mouse model 
was generated in 2000 by Lauzurica et al14. This group showed that CD69-/- mice presented normal 
hematopoietic and T-cell development in the thymus and periphery and also similar NK cytotoxic 
activity as wild type (WT) mice. In contrast, B-cell development in CD69-/- was affected as a specific 
bone marrow pre-B cell compartment (B220hiIgMneg) was induced in the absence of CD69. The 
knockout mice presented besides a small increase in immunoglobulin (Ig) G2a- and IgM-responses to 
immunization with T-dependent and T-independent antigens14. Apart from the observation on the role 
of CD69 in B-cell development, CD69-deficient mice displayed an enhanced susceptibility to several 
inflammatory diseases, mediated by T helper (Th) 17 cells15, 16.  
 
1.4. Immunoregulatory role of CD69 in experimental pathologies 
 
In vivo studies using CD69-/- mice uncovered a key role of CD69 as an immunoregulatory player 
during immune responses17. It has been proposed as a negative regulator of autoimmune reactivity for 
conditions including collagen induced arthritis (CIA)18, anti-tumor responses19, allergic asthma and 
skin contact hypersensitivity20, autoimmune myocarditis21 as summarized in Table 1. In the case of 
CIA, allergic asthma and cardiomyopathy, CD69-/- mice displayed an exacerbated inflammatory 
response. However, in another study in which murine arthritis was induced by anti-type II collagen 
murine antibody (mAb), the CD69-deficient mice showed a remarkably attenuated neutrophil-
mediated inflammation compared with WT mice22, 23. This could be due to the fact that a different 
experimental procedure has been applied to the study or because the strain of used CD69-deficient 
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mice varied depending on the study. In addition, the chemical stimulus that is used each time in order 
to provoke or control an inflammatory response in a designed study could vary, causing the role of 
CD69 in immunoregulation to vary as well. The collective data above indicate a dual role of CD69 in 
inflammation: on the one hand as a negative regulator in a lymphocyte- and NK-dependent manner, 
and as a positive regulator in acute inflammatory responses mediated by neutrophils22, on the other. 
 
	  
Table 1. CD69’s regulatory role in animal model diseases (adapted from González-Amaro et al, 2013). 	  
Disease	   Mouse	  model	   Mediated	  by	  	   Tissue	   References	  
Collagen-­‐induced	  arthritis	   C57BL/6J	  CD69-­‐/-­‐	   T	  and	  B	  cells	   Synovial	  leukocytes	   18	  
Anti-­‐type	  II	  collagen-­‐
induced	  arthritis	   C57BL/6J	  CD69-­‐/-­‐	   Neutrophils	   Joints	   22,	  23	  
Ovalbumin-­‐induced	  
allergic	  airway	  
inflammation	   Balb/c	  CD69-­‐/-­‐	   Th2/Th17	  	   Lungs,	  airways	   20,	  24	  
Lung	  inflammation	  
induced	  by	  bleomycin	   C57BL/6J	  CD69-­‐/-­‐	   Macrophages,	  neutrophils,	  lymphocytes	   Lungs	   25	  
Cigarette	  smoke-­‐induced	  
inflammation	   C57BL/6J	  CD69-­‐/-­‐	   Macrophages,	  neutrophils	   Lungs	   26	  
Contact	  hypersensitivity	  
to	  oxazolone	   C57BL/6J	  CD69-­‐/-­‐	   Th1/Th17	   Skin	   20	  
Experimental	  
autoimmune	  myocarditis	   Balb/c	  CD69-­‐/-­‐	   Th17	  	   Myocardium	   16	  
Systemic	  lupus	  
erythematosus	   NZBxNZW	  mice	   CD4+CD69+	  T	  cells	   Peripheral	  lymphoid	  tissues,	  kidney,	  lungs	   27	  
Listeria	  monocytogenes	  
infection	   C57BL/6J	  CD69-­‐/-­‐	   Th1	   Liver,	  spleen	   28	  
CD4	  T	  cell	  transfer	  colitis	   C57BL/6J	  CD69-­‐/-­‐	   Th1	   Bowel	   15	  
 
 
1.5. CD69 in human pathologies 
 
Beside animal-based data, early studies suggested that CD69 might also play an important role in 
human diseases and tissue damage-associated inflammation through the activation of leukocytes2, 4, 17, 
as summarized in Table 2. 
 
Biopsies from patients suffering from rheumatic diseases (rheumatoid arthritis (RA) and 
osteoarthritis) have shown that CD69 is overexpressed in the joints and synovial fluid, and it is 
apparently connected with the pathogenesis and/or progression of these pathologies9.  
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Table 2. Implication of different cells in CD69-mediated regulation in selected human pathologies (adapted 
from González-Amaro et al, 2013). 	  
Disease	   Cells	   Tissue	   References	  
Rheumatic	  diseases	   	   	   	  
Rheumatoid	  arthritis	   T	  and	  NK	   Synovial	  fluid	   9,	  29,	  30	  
Osteoarthritis	   T	  cells	   Synovial	  membrane	  and	  fluid	   30	  
Autoimmune	  diseases	   	   	   	  
Multiple	  sclerosis	   Th17	   Cerebrospinal	  fluid	   31,	  32	  
Inflammatory	  diseases	   	   	   	  
Chronic	  bronchitis	   CD4+	  T	  cells	   Peripheral	  blood,	  lung	   33,	  34	  
Other	  diseases	   	   	   	  
Asthma	   T	  cells,	  eosinophils	   Peripheral	  blood,	  lung	   35-­‐37	  
Kidney	  transplant	   Treg	   Peripheral	  blood,	  kidney	   38,	  39	  
 
 
Furthermore, in patients with RA CD69 is constitutively overexpressed in most of the T and NK cells 
from the synovial fluid and it participates in the expression induction of the pro-inflammatory 
mediator TNF-α in macrophages29, 40. Similarly to RA, high number of CD69-expressing (CD69+) 
leukocytes has been observed in the synovial fluid from osteoarthritis patients30. 
 
Furthermore, increased levels of CD69+ cells have been linked with an autoimmune disease, multiple 
sclerosis (MS); the cerebrospinal fluid of MS patients contains an abundant population of 
CD4+CD69+ lymphocytes and is characterised by increased pro-inflammatory interferon (IFN)-γ and 
TNF-α production31, 32. It has also been demonstrated that these patients displayed an increased Th17 
response; thus suggesting that CD69+Th17+ cells might have a potent pathogenic role41. 
 
Regarding inflammatory diseases, it appears that some CD69+ cells are able to stimulate an 
inflammatory environment. For example in the case of atherosclerosis, the disease outcome is 
correlated with the percentage of the CD69+ lymphocytes in atheroma plaques according to a recent 
study34. Finally, although CD69-expressing regulatory T cells (Treg), which are a subset of 
lymphocytes T, had an immunosuppressive role in asthma and kidney transplantation, the majority of 
CD69-positive T cells exerted a pathologic role in the progression of these diseases42. 
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Although CD69 was first studied primarily in human pathologies and was believed to be a positive 
immune regulator, further studies on CD69-deficient mice provided evidence that this molecule exerts 
a negative regulatory role in immune response. The fact that high expression of CD69 is observed in 
different human biopsies does not necessarily mean that this molecule participates exclusively in the 
activation of the inflammatory response. Instead, it rather indicates that CD69 is necessary to 
modulate inflammation in order to protect from an exacerbated response, and is therefore highly 
expressed. 
 
1.6. CD69+ Treg cells 
 
Regulatory T cells are important in the control of self-reactivity and in the pathogenesis of 
autoimmune inflammatory conditions, in which they might display an immunosuppressive role. In 
particular, the CD69+ Treg subset has been linked with anti-inflammatory functions. Besides, CD69 
molecule plays role in the differentiation of Tregs from the human thymus, as described by Martin-
Gayo et al43. They reported that CD69 expression induces the differentiation of CD4+CD8+CD69high 
thymocytes into CD4+CD25highFoxp3+ Treg cells43. It was supported by the observation that CD69-/- 
mice presented a reduced capacity of CD4+CD69+ lymphocytes to differentiate into Treg cells15. 
 
The existence of another Treg cell subset, i.e. the CD69+CD4+CD25- population, suppressing T cell 
proliferation and regulated by membrane-bound TGFβ, has also been reported in mice44. Accordingly, 
in the peripheral blood from patients with thyroid disease, two subpopulations of CD69-expressing 
Treg lymphocytes, CD69+TGFβ+ and CD69+IL-10+, have been found45. Furthermore, Gandhi et al. 
described the TGFβ+group, pointing out to their strong immunosuppression46. In this regard, patients 
with systemic lupus erythematosus presented an increased CD69+CD4+ lymphocyte population, 
probably due to their immunosuppressive functions47. Overall, these data confirm that CD69, 
expressed in different Tregs, including highly immunosuppressive populations, is important for their 
development and cellular activity. 
 
 
2. Th17 and Treg cell differentiation  
 
T cells can differentiate, among others, into Th17 and regulatory Tregs. Th17 cells, a subset of T 
helper cells, primarily secretes interleukin (IL)-17 in addition to other pro-inflammatory cytokines, 
related to many autoimmune and chronic inflammatory diseases48. There is a balance between Th17 
and Treg cells that highly depends on the activation of the transcription factors: retinoic acid 
receptor–related orphan receptor (RoR) (γ)t and signal transducer and activator of transcription (Stat) 
3, or forkhead box (Fox) P3 and Stat5, respectively, which regulate the immune response through the 
	  	  |	  P a g e 	  	   28	  
secretion of pro- and anti-inflammatory cytokines49-52 (Figure 2). On the other hand, the importance 
of Treg cells in the maintenance of peripheral tolerance in non-inflammatory conditions throughout 
life has also been confirmed. In fact, mice lacking Treg cells demonstrated a fatal inflammatory 
response53, 54. 
	  
The primary cytokines involved in Th17 and Treg cell differentiation are transforming growth factor 
(TGF) β and IL-655-57 (Figure 2). IL-6 is strongly induced in cells of the innate immune system upon 
stimulation of pattern recognition receptors such as toll-like receptors (TLR) and C-type receptors. It 
has been shown that mice lacking IL-6 exhibit a deficiency in the differentiation of effector T cells58, 
59. TGFβ induces Foxp3 in the absence of IL-6, thus pushing T-cell differentiation away from the 
Th17 transcriptional program and toward the Treg lineage52, 60. In contrast, the pro-inflammatory 
cytokine IL-6 in the absence of TGFβ activates Stat3 by phosphorylation, which overcomes Foxp3 
inhibition of RoR(γ)t transcriptional activity. This process leads to the up-regulation of the IL-23 
receptor (IL-23R), promoting the T-cell differentiation toward the Th17 fate52. Therefore, the cytokine 
environment is essential for the predominance of either Th17 or regulatory T cell response. 
 
 
 
Figure 2. The role of TGFβ  and IL-6 as key elements involved in pushing T cell differentiation into Treg or 
Th17 cells. 
 
 
2.1. Th17 in fibrotic diseases 
 
Fibro-proliferative diseases such as idiopathic pulmonary, liver, cardiovascular and renal fibrosis are 
usually associated with chronic inflammation, as previously reported61-65. When an inflammatory 
response becomes chronic, the accumulation of extracellular matrix (ECM) is more extensive and the 
function of the organ becomes compromised. A number of studies have highlighted the role of 
Th17/Treg/Th1/Th2 responses in the pathogenesis of tissue fibrosis66, 67. 
	  	  |	  P a g e 	  	   29	  
Among these responses, Th17 cells mediate strong inflammation by producing a cocktail of cytokines 
such as IL-6 and IL-17, among which IL-17 has been recently characterized as a major effector 
cytokine in causing a sustained inflammatory response. Also, recent studies have revealed the role of 
Th17 response in fibrosis. Specifically, it has been reported that administration of IL-17A in vitro into 
alveolar epithelial cells increased the synthesis and secretion of collagen. Moreover, all IL-17-
associated signalling pathways were activated in fibrotic lung biopsies in a pulmonary fibrosis model; 
on the other hand, a blockade of IL-17 attenuated tissue injury, inflammation and fibrosis in that 
protocol68. Furthermore, IL-17 is involved in the pathogenesis of chronic liver fibrosis64, 69-71. IL-17-
dependent mechanism of liver damage was confirmed in chronic hepatitis B patients, who presented an 
elevated Th17 cells population72. As for Th17 lymphocytes, they also play a crucial role in 
autoimmune myocarditis, showed by in vitro and in vivo experiments that linked IL-17 induced cardiac 
fibrosis with the activation of the protein kinase C-β/Erk1/2/NF-κB pathway73. Similarly to previous 
data, the regulatory role of CD69 was associated with the modulation of Th17 responses, resulting in 
attenuated myocardial inflammation, fibrosis and heart failure21.  
 
Recent studies have shown the importance of Th17 cells and its hallmark cytokine IL-17 in immune-
mediated kidney disorders called glomerulonephritis and lupus nephritis74, 75. Th17 cells participate in 
renal damage; mice receiving Th17 cell injections displayed albuminuria and neutrophils infiltration 
into kidney76. Elevated renal production of IL-17 by Th17 cells was also found in non-immune 
experimental renal diseases, including a model of unilateral ureteral obstruction77. In experimental 
ischaemia reperfusion, neutrophils, but not Th17 cells, were the main sources of IL-17 and contributed 
to renal injury by T cells activation by NK and IL-12 and IFN-γ production78. In renal damage and 
allograft rejection model, positive staining for IL-17 has been detected in tubular cells 79, suggesting 
that renal cells could produce this cytokine as well and thus contribute to the kidney failure. Using the 
same model it was demonstrated that a blockade of IL-17 diminished renal inflammation77. Based on the 
above and other studies80, IL-17 has been proposed as a target for treatment of fibrotic diseases. 
 
2.2. Treg in fibrotic diseases 
 
Although an induced Th17 response is connected to fibrogenesis, a relative decrease in the number of 
Treg cells might also be involved in the pathogenesis of inflammatory and fibrotic diseases. The 
evaluation of these cells in the context of experimentally induced fibrosis has been challenging, and 
Tregs depletion in mice has been demonstrated to promote the development of lung fibrosis81. In an 
experimental animal model of cardiac fibrosis, the adoptive transfer of isolated Tregs ameliorated 
cardiac fibrosis, indicating a protective role of regulatory T cell in tissue fibrosis82. It has recently been 
reported that Treg cells are essential for preventing the accumulation of fibrocytes and collagen in a 
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pulmonary disease animal model. In this study, it was shown that a blockade of Treg cells increased 
the accumulation of solid collagen and progression of the disease83. Finally, in another study (Keloid 
fibrotic disease) the potential role of Treg cells in attenuating collagen synthesis was investigated. This 
group found the imbalance of Tregs might contribute to the development of this fibrotic disease and 
the correction of this imbalance could be of therapeutic value 84.  
 
 
3. CD69 regulates the Th17 and Treg cell differentiation 
 
It has been reported that combined treatment with low dose of phorbol ester (mitogenic factor, 
activator of protein kinase C) and monoclonal antibody against CD69 (causing CD69 activation) 
triggered Ca2+ influx and the ERK1/2 pathway induction. Subsequently, expression of IL-2, IFN-γ 
and increased Treg cell proliferation were observed. These data were the first to suggest that the 
CD69 receptor could be involved in the category of pro-inflammatory receptors that induce leukocyte 
activation2, 4. The group of Martín et al. (2011) reported that the cytoplasmic tail of the CD69 receptor 
associates with Jak3 kinase, which positively interacts with a transcription factor Stat5, regulating in 
turn another transcription factor FoxP3, important for T cell differentiation into Treg. On the other 
hand, CD69 might inhibit Th17 differentiation: (i) by phosphorylating Stat5, which blocks the 
phosphorylation of Stat3 (positive regulator of RoR(γ)t and Th17) and (ii) by antagonizing Stat3-
mediated activation through FoxP3 activation on Stat5 activation85, 86 (Figure 3). 
 
3.1. CD69 negatively regulates Th17 differentiation 
 
The importance of CD69 in different pathological models (such as contact dermatitis, allergic asthma 
and autoimmune myocarditis) was highlighted by in vivo studies, using CD69-deficient mice. The 
genetic ablation of the protein resulted in exacerbated reactions in these knockout mice (e.g. high 
susceptibility to developing asthma)20, 21. Interestingly, a blockade of the CD69 expression, by 
introducing a neutralizing antibody into WT mice, also showed an increased inflammatory response in 
the lungs in allergic asthma model. Importantly, this altered response in CD69 knockout mice was 
linked with augmented T cell activity in damage sites. Specifically, CD69-deficient mice displayed 
enhanced T cell responses in the lungs. These observations suggested CD69 as a candidate molecule 
regulating immune allergic responses by decreasing T cell effector responses. Moreover, in a model 
of experimental autoimmune myocarditis CD69-deficient mice presented induced Th17 cells in the 
heart followed by cardiac inflammation21.  
 
A number of in vitro studies further described the CD69-dependent reactions as negative modulators 
of inflammatory responses, mediated among others by IL-17-secreting T (Th17) lymphocytes. It was 
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shown, that CD69 regulates the generation and functions of Th17 cells. For instance, the absence of 
CD69 enhanced the differentiation of T cells into Th17 cells in vitro and was associated with T cells 
activation and transcriptional induction of molecules required for this process, such as RoR(γ)t, Stat3 
and IL-2349-51 (Figure 3). 
 
 
Figure 3. CD69 regulates Th17 and regulatory T cell differentiation. MHC II: major histocompatibility complex 
II; P: phosphorylation. Dashed lines indicate indirect effects or interactions, and multiple arrows indicate 
multistep processes (adapted from Martín et al., 2011). 
 
Th17 cells from CD69-deficient mice also produced lower amounts of IL-2 and showed decreased 
activation of Stat5, compared with the cells from WT mice86. The affected Stat5 phosphorylation, 
which is a negative regulator of Stat3 activation, led, in turn, to higher activation of Stat3 in CD69-
deficient Th17 cells, an event that favors their differentiation87, 88. Further evidence of CD69 
implication in Th17 differentiation was delivered by introducing exogenous IL-2 into CD69-deficient 
T cells. The exogenous IL-2 restored Stat5 activation and, thereby, blocked Th17 differentiation. 
Moreover, in contrast to WT cells where blocking of IL-2 inhibited Stat5 activation and promoted 
differentiation, CD69-deficient cells displayed no effect to this IL-2 inhibition. CD69 thus promotes 
Stat5-mediated inhibition of Th17 cell differentiation independently of the IL-2 pathway86 (Figure 3).  
 
In conclusion, the above evidence points to CD69 as a key molecule in negatively regulating Th17 
differentiation. 
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3.2. CD69 positively regulates Treg cell differentiation 
 
It has been observed that plasma of patients suffering from systemic sclerosis, which contained low 
numbers of Treg cells, simultaneously, had diminished expression of the CD69 receptor on the 
surface of blood cells89. It was therefore postulated that CD69 might influence the Treg-dependent 
immune response. 
 
It has been shown that CD69 impairs the function of sphingosine 1-phosphate receptor 1 (S1P1), 
normally involved in the migration of lymphocytes from lymphoid tissues to organs during so called 
recirculation, a process essential for immune surveillance90. Accordingly, in the absence of CD69 
there were increased levels of S1P1 and increased migration of T lymphocytes into lymph nodes or 
inflamed tissues91. A high expression of S1P1 in CD4+ T cells was associated with abundant IL-17 
secretion, and, consequently, enhanced Th17 differentiation92. Additionally, the absence of CD69 and 
low concentration of S1P1 led to the differentiation of CD4+CD25+FoxP3+ expressing cells, thus 
pointing to Treg cell fate93. In regard to this, in a mouse model of contact sensitization, S1P1 promotes 
migration of dendritic cells94 and the CD69 deficiency increases the abundance of S1P1, enhancing the 
ability of these cells to migrate in vivo and in vitro85. Therefore, CD69 might modulate the balance 
between the Th17 and Treg cells, thus contributing to a resolution of inflammatory response. 
 
 
4. PD as an alternative therapy in renal failure diseases 
 
When the function of the kidneys diminishes to 10 – 15%, the individual needs therapy to replace 
renal function to sustain life, which is why techniques that clean the blood or kidney transplantation 
have been introduced. Patient with impaired renal function suffer from uremia, a term that was 
described for the first time by Piorry et al. in 1840. Uremia was defined as set of symptoms at the 
systemic level, produced as a result of the accumulation of toxic products in the blood that are 
retained in the kidney with dysfunction, instead of being eliminated. 
 
Peritoneal dialysis (PD) is a form of renal replacement therapy that has become an alternative to 
hemodialysis95-97. It has been used for approximately three decades as a treatment for end-stage renal 
diseases. However, the two first decades were marked by frequent improving catheter designs, 
technical aspects and peritonitis control95, 96. During the last 10 to 15 years, great effort was made to 
improve the biocompatibility of the solutions with the hope of diminishing their adverse effects on 
peritoneal morphology and function98-102. PD offers major advantages in terms of quality of life, cost 
and home-based treatment opportunities compared with the haemodialysis. Undoubtedly, the increase 
of PD programs could also be attributed to improvements in the PD technique, especially in terms of 
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peritonitis prevention, and to the biocompatibility of the dialysis solutions. At present, PD is a 
successful treatment for end-stage renal disease, and several studies have confirmed equivalent 
adequacy, mortality, and fluid balance status when compared with haemodialysis, at least for the first 
4-5 years of treatment103-106. However, the growth of PD continues being limited by the membrane’s 
incapacity to perform adequate diffusive and/or convective transports at long-term97, 107. Ultrafiltration 
failure and fibrosis of the peritoneum are the primarily complications during PD treatment. 
 
4.1. Peritoneal cavity and peritoneal membrane 
 
The peritoneal cavity is the largest cavity of the body and harbours the major internal organs 
belonging to the tractus digestivus, including the spleen, pancreas and liver. In physiological 
conditions, the most abundant cell type in the abdominal (peritoneal) fluid are macrophages (80%), 
known as the first line of defence against pathogens108. The remaining cell population consists of 
peritoneal T lymphocytes, eosinophils, dendritic cells, mast cells and mesothelial cells. 
 
The peritoneal membrane (PM), which covers the entire peritoneal cavity, is divided into the parietal 
peritoneum and the visceral peritoneum. The parietal peritoneum covers the inner surface of the 
abdominal wall, whereas the visceral peritoneum covers the surface of the intraperitoneal organs. The 
total surface area of the peritoneum of adult subjects is approximately 1 m2 composing to 10-15% of 
the parietal peritoneum and 85-90% of either the visceral or hepatic. Structurally, the peritoneal 
membrane consists of two layers: the mesothelium and the interstitium, supported on the muscles rich 
in peritoneal vessels109, 110 as represented in Figure 4. 
 
Mesothelial cells (MCs), connected to each other by intercellular junctions111, form a compact 
monolayer covering the peritoneal membrane and are the most numerous cells in the peritoneal 
cavity. Under normal condition MCs play a crucial role in peritoneal homeostasis, including anti-
adhesive and fibronolytic mechanisms, regulation of local blood circulation and vessel permeability, 
regulation of matrix formation and local defense mechanisms112, 113. They produce prostaglandins114, 
cytokines115, chemokines116 and factors modulating local hemodynamic such as nitric oxide117. MCs 
also orchestrate the local inflammatory response during peritoneal injury, as described below. 
 
Mesothelium covers the layer of interstitium and a compact zone of muscles from within118 (Figure 
4). The former is built up by loose connective tissue composed of collagen fibers, proteoglycans and 
other extracellular matrix (ECM) compounds and, in healthy individuals, contains small numbers of 
fibroblasts, macrophages, and mast cells. Some vessels are also present in the interstitium119.  
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4.2. PD technique 
 
The aims of PD technique are the elimination of the small toxic molecules from the blood when these 
molecules cannot be eliminated in a normal situation and the elimination of excess of water. It 
requires the instillation and periodical renovation of a hyper-osmotic dialysate liquid, peritoneal 
dialysis fluid (PDF) through a permanently installed catheter in the peritoneal cavity. The instilled PD 
fluid creates an ideal environment for the exchange of the toxic molecules from the blood to the 
peritoneal cavity through the PM. 
 
 
Figure 4. Schematic representation of healthy peritoneal membrane (insert on the right) in a patient undergoing 
PD therapy. 
 
 
4.3. Inflammatory stages and fibrosis  
 
During the PD treatment, the peritoneal cavity is exposed to an average of 2200-7000 liters of PD 
fluids per year120 and the patient can remain on this treatment for years. During peritoneal dialysis, 
patients’ biopsies change, revealing the disappearance of mesothelial cells121 or their conversion to 
fibroblastic cells (in a process of mesothelial to mesenchymal transition or MMT)122, angiogenesis123 
(formation of new vessels) and fibrosis of the PM (accumulation of ECM and collagen in the 
peritoneum)124.  
 
The non-physiological nature of PD fluids and episodes of peritonitis appear to be the primary 
etiologic factors leading to the functional decline of the peritoneal membrane97, 102, 125 and eventually 
fibrosis. Such alterations are considered the major cause of ultrafiltration failure and the loss of 
dialytic capacity of the peritoneum during peritoneal dialysis. All these phenomena during PD lead to 
an incapacity of the peritoneal membrane to discharge the toxic molecules from the blood, which is 
called ultrafiltration failure96 (Figure 5). 
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                             Normal peritoneum                     Early PD                         Long-term PD  
 
Figure 5. Schematic representation of the progressive alterations of the peritoneal membrane during evolution 
of PD. Angiogenesis, vasculopathy, mesothelial to mesenchymal transition and fibrosis are the primary 
alterations that deregulate the function of the peritoneum during PD (from López-Cabrera, 2014). 
 
The primary alteration in the peritoneal membrane in patients undergoing PD is the development of 
fibrosis. A variable degree of diffuse peritoneal fibrosis has been documented in these patients. It 
might have only a moderately detrimental effect on peritoneal transport kinetics, or might be 
manifested by a progressive, sclerosing, encapsulating peritonitis, which can lead to cessation of 
peritoneal dialysis and to death. An accompanying ECM expansion is a combination of increased 
ECM production, as a consequence of increased proliferation of fibroblasts126, 127, biochemical 
modification of the matrix by advanced glycation end product (AGE) formation and reduction in 
ECM degradation128. 
 
4.4 Episodes of peritonitis  
 
Episodes of peritonitis which involve inflammation of the peritoneum, are one of the primary causes 
for functional decline of the peritoneal membrane during PD. Peritoneal infections are frequently 
caused by Staphylococcus epidermidis, Staphylococcus aureus or Escherichia coli129. During these 
episodes, the immune cells are attracted to the peritoneal cavity, causing a strong inflammatory 
response attracting T cells and the macrophages arrive to the peritoneal cavity. As for CD4+ T cells 
(Th), they can be classified according to their phenotype: Th1 and Th2. In general, Th1 lymphocytes 
produce increased IFN-γ essential for the activation of macrophages75, whewreas Th2 lymphocytes 
secrete IL-4, activating the function of B cells. Studies performed during episodes of peritonitis on 
patients undergoing PD, revealed a very strong induction of the Th1 response and increased 
expression of cytokines such as IL-1β130 and IFN-γ,131 with a concurrent increase of other Th1-related 
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cytokines. If the inflammatory response is persistent or a peritonitis episode recurs, the risk for 
peritoneal damage increases, ultimately resulting in a loss of peritoneal function. Therefore, episodes 
of peritonitis are crucial to the outcome of PD treatment. 
 
4.5 Pathogenesis of peritoneal membrane dysfunction 
 
It is generally believed that uremic status can affect, to some extent, the architecture of the peritoneal 
membrane and its transport characteristics. It was observed that the peritoneal membrane of partially 
nephrectomised PD-treated rats increased its permeability, which was associated to up-regulation of 
nitric oxide synthase (NOS) isoforms, vascular endothelial growth factor (VEGF), and fibroblast 
growth factor (FGF)-2, and accumulation of AGEs132. Despite these findings in animal models, the 
effect of uremia itself on the human peritoneum is debated. Two human peritoneal biopsy studies 
have shown a modest compact zone thickening and vasculopathy in pre-dialysis renal patients123, 133. 
In contrast, other studies found no significant fibrosis or vasculopathy in uremic non-PD patients134. 
 
The bio-incompatible nature of PDF together with the episodes of bacterial infections (peritonitis) 
mentioned above are being considered as the main factors guiding to the peritoneal damage and 
peritoneal dysfunction. These events can produce an inflammatory environment and damage the 
peritoneal membrane97, 102, 125, 135, 136. The peritoneal immune response to these factors involves MCs 
and resident macrophages that work in a coordinated manner to recruit other inflammatory cells, 
including mononuclear phagocytes (macrophages and monocytes), lymphocytes and neutrophils. 
Furthermore, MCs and infiltrating immune cells produce a wide range of cytokines, growth factors 
and chemokines to establish a complex network that results in acute or chronic inflammation136-138 as 
summarised in Table 3 and Figure 6. 
 
In 2010, Zhang et al.139 found that the plasma of uremic patients undergoing haemodialysis contained 
increased numbers of Th17 cells and decreased Treg cells, and, accordingly, increased expression 
levels of Th17-related cytokines (IL-17, IL-6 and IL-23) and decreased levels of Treg-related 
cytokines (e.g. IL-10 and TGFβ), when compared with healthy individuals. Another study reported 
that IL-17 was overexpressed in peritoneal membrane in human biopsies from PD patients and in PM 
from PD-treated mice140. Recently, our group revealed that WT mice treated with PD fluid were 
characterised by increased IL-17 level in the peritoneal cavity fluid141. 
 
Previous studies on PD in clinic have demonstrated that in the absence of peritonitis episodes, the 
patients also had a considerable percentage of inflammatory cells in the peritoneal cavity compared 
with healthy individuals. Along these lines, Lewis et al.142 suggested there was a certain degree of cell 
activation in the peritoneal cavity during PD, including the cases where the peritonitis episodes were 
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absent. This statement was based on previous studies, in which the percentage of lymphocytes was 
elevated in the peritoneal cavity during PD, primarily in the first month of treatment142. On the other 
hand, other authors found different proportions between CD4 and CD8 cells in the peritoneum during 
PD compared the healthy individuals143, 144. Moreover, a role for Th2 cells in patients under PD 
treatment has also been proposed145. However, other studies refer to Th1 cells and their primary 
secreted cytokine IFN-γ, as major participants of the immune response during PD146 (Figure 6). 
 
 
Figure 6. Schematic representation of the immune cells and their corresponding factors released into the 
peritoneal cavity, upon exposure of the peritoneum to PD fluids. 
 
 
Furthermore, regarding B cells and their function during PD, there are studies that reported their 
decrease during the first two years of PD144, 147. B1 cells (the primary subpopulation of B cells in the 
peritoneal cavity148) might modify the phagocytic activity of macrophages in vitro due to secretion of 
IL-10149. 
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Macrophages are the most abundant cell population during PD. In a study carried out by Ganguly et 
al. in 1980, they observed that in stable PD patients, the macrophages in drained PD fluids were 
approximately 72%, whereas the lymphocytes comprised only 14%150. 
 
The concentration of cytokines and chemokines secreted from specific cell populations during PD are 
also increased. For example, the level of intraperitoneal IL-6 is increased during dialysis treatment, 
compared with healthy individuals151. 
 
A sustained inflammation manifested by accumulation of pro-inflammatory cells, secretion of related 
cytokines might trigger the fibrogenic and angiogenic processes associated with ultrafiltration failure. 
 
Table 3. Functions of cytokines and chemokines present in the peritoneal cavity. GMCSF: granulocyte 
macrophage colony-stimulating factor; MCP: monocyte chemoattractant protein; RANTES: regulated on 
activation, normal T cell expressed and secreted; MIP: macrophage inflammatory protein 
Cytokines/	  
chemokines	   Secreted	  from	   Function	  
IL-­‐1α 	   Monocytes	  and	  other	  152	   v Pro-­‐inflammatory.	  Active	  COX-­‐2	  152	  
IL-­‐2	   T	  cells	  153	   v Activation	  of	  T	  cells,	  monocytes	  and	  B	  cells153	  
v Proliferation	  of	  T	  cells	  153,	  154	  
IL-­‐4	   Th2	  cells	  154	   v Pro-­‐fibrotic	  63	  
v Differentiation	  of	  T	  &	  B	  cells	  153	  
IL-­‐5	   Th2	  cells	  153,	  154	   v Differentiation	  of	  B	  cells	  in	  mice	  153	  
v Increase	  Th2	  154	  
IL-­‐6	  
Monocytes,	  macrophages,	  T	  and	  B	  cells,	  fibroblasts	  neutrophils,	  adipocytes	  151,	  153-­‐155	  
v Promote	  inflammation	  due	  to	  MCP-­‐1	  release	  156	  
v Activate	  monocytes	  and	  macrophages	  
v Activate	  T	  lymphocytes	  
v B	  cell	  differentiation	  157	  
v Leukocyte	  recruitment	  157	  
v Proliferation	  of	  fibroblasts	  
IL-­‐10	  
Th2	  cells,	  monocytes,	  B	  cells,	  Tregs,	  Th17	  cells	  153,	  158,	  159	   v Anti-­‐inflammatory	  action	  v Reduce	  the	  production	  of	  IL-­‐6	  160	  
IL-­‐17	   Th17	  cells	   v Pro-­‐inflammatory	  mediator.	  Induce	  the	  release	  of	  GM-­‐CSF.	  v Related	  to	  fibro	  proliferative	  diseases	  caused	  by	  infections	  161,	  162	  autoimmunity	  163	  
MCP1	  
Mesothelial	  cells	  164-­‐166,	  fibroblasts,	  monocytes,	  macrophages	   v Recruitment	  and	  activation	  of	  monocytes	  167	  and	  T	  cells	  155,	  168	  v Induced	  in	  different	  models	  of	  fibrosis	  169-­‐171	  
MCP3	   Activated	  monocytes	  172	   v Leukocyte	  activation	  	  v Attract	  monocytes	  and	  T	  lymphocytes	  168	  
v Implicated	  in	  fibrotic	  diseases	  172	  
RANTES	   T	  cells	   v 	  Attract	  monocytes	  and	  T	  lymphocytes	  v Activate	  T	  cells,	  monocytes	  and	  neutrophils	  
MIP1α 	  
MIP1β 	  
Monocytes,	  macrophages,	  endothelial	  cells,	  fibroblasts	  and	  T	  cells	  173	  
v Neutrophil	  recruitment	  174	  
v MIP1α:	  chemotaxis	  of	  B	  and	  T	  CD8+	  activated	  173	  
v MIP1β:	  chemotaxis	  of	  T	  CD4+	  activated	  173	  
v Both	  are	  associated	  with	  Th1	  response	  
v 	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4.6. MMT as a factor triggering peritoneal fibrosis 
 
The bio-incompatible nature of PDF appears to be a factor triggering the inflammatory response. 
However, another phenomenon takes place during PD known as mesothelial to mesenchymal 
transition (MMT), which is implicated in the complex scenario of peritoneal damage.  During PD the 
MCs of the peritoneal membrane gradually lose their polarity and convert into myofibroblasts179, 180 
(Figure 5 and 6). Myofibroblasts were first described by Gabianni et al. in 1972; they play an 
important role in fibrosis181. This is in line with their capacity to synthesize ECM, cytokines and 
chemokines and promote an inflammatory response. 
 
Although myofibroblasts are present neither in normal peritoneum, nor in peritoneum of uremic-non 
PD patients134, 182 they are present in patients undergoing PD.134, 182-184 It was demonstrated for the first 
time in 2003 that the conversion of mesothelial cells into myofibroblasts (MMT) is present during 
PD185. The authors reported that soon after PD was initiated, peritoneal MCs showed a progressive 
loss of epithelial phenotype and acquired myofibroblast characteristics185. However, definitive proof 
demonstrating that the PD-induced MC phenotype changes were related to a MMT process came from 
the analysis of the expression of several mesenchymal markers including transcription factor Snail, N-
cadherin, fibronectin, collagen I, α-smooth-muscle actin (α-SMA) and fibroblast specific protein-1 
(FSP-1), which were gradually up-regulated in effluent MCs with epithelioid and non-epithelioid 
phenotypes135, 136, 185, 186. 
 
Therefore, MMT is an important inducer of peritoneal damage and fibrosis due to the conversion of 
MCs into myofibroblasts producing large amounts of extracellular matrix components (fibronectin, 
collagens) and wide range of inflammatory, pro-fibrotic and angiogenic factors (VEGF, TGFβ, IL-8, 
IL-6). The overall effect of these changes is the structural and functional deterioration of the 
peritoneal membrane97, 122, 135, 136. 
 
4.7 Bio-incompatible PD solutions as a source of inflammation 
IFN-­‐γ 	   Τ	  and	  NK	  cells	  154	   v Activate	  macrophages,	  epithelial	  and	  endothelial	  cells	  154	  v Promote	  migration	  of	  the	  leukocytes	  155	  
v Inhibit	  collagen	  production	  in	  vitro	  and	  α-­‐SMA	  expression	  155	  
GMCSF	   Activated	  T	  cells	  &	  macrophages	  154	   v Proliferation	  and	  differentiation	  of	  granulocytes/macrophages	  progenitors	  
TNF-­‐α 	   Macrophages,	  fibroblasts	   v Neutrophil	  recruitment	  v Th1	  cytokine	  155	  
TGFβ 	   Fibroblasts,	  immunologic	  cells,	  macrophages	  63,	  175	   v Regulate	  ECM	  formation,	  migration	  and	  apoptosis	  176,	  177	  v Pro-­‐	  or	  anti-­‐inflammatory	  action	  178	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The principal cause of inflammation is the bio-incompatibility of the PD fluids used during PD. The 
primary factor contributing to this bio-incompatibility is the high concentration of glucose-derivatives 
present in PD fluids. An appropriate osmotic capacity of the PD fluid is necessary for elimination of 
toxic molecules from the blood and their transport towards the peritoneal cavity. It is achieved by 
high glucose concentration which is 15 – 40 times as concentrated as in normal abdominal fluid120. 
The mesothelial layer of the peritoneum is the first line of contact with the PD fluid. It has been noted 
that high concentrations of PD fluid in human peritoneal mesothelial cells (HPMCs) induce the 
synthesis of TGFβ, which is implicated in fibronectin production (forming ECM) and fibrosis187. 
Furthermore, the exposure of HPMCs to glucose products can provoke apoptosis188. 
 
The sterilization of PD fluids is primarily performed by heating. This might give rise to the 
appearance of high glucose degradation products (GDPs). The GDPs activate inflammatory cells and 
induce apoptosis of mesothelial cells189. For example the exposure of HPMCs to GDPs induces the  
secretion of high levels of IL-6 and pro-angiogenic factor, VEGF from these cells190, 191 (Figure 7). 
 
Another factor affecting the biocompatibility of the PD fluids are AGEs. These products can react 
with collagen fibers (component of the ECM). Solubility of these fibers increases, making them more 
resistant to degradation, thus favoring the deposition of collagen and provoking fibrosis during PD95. 
Moreover, the receptor for AGEs (RAGE) is mainly present on mesothelial cells, endothelial cells, 
macrophages and fibroblasts192-194, all capable of triggering an inflammatory response. There is 
evidence that the conversion of mesothelial to mesenchymal cells is mediated, at least in part, by 
RAGE195. For this reason upon exposure to PD fluid the mesothelial cells might acquire fibroblastoid 
characteristics and modify the expression of molecules implicated in the generation of ECM and 
could secrete many pro-inflammatory cytokines and chemokines such as MCP-1, IL-1, IL-6, IL-10, 
TGFβ and RANTES (Figure 6 and 7). Fibroblasts can also secrete these pro-inflammatory molecules 
in response to AGEs193, 196 (Figure 7). 
 
Furthermore, the binding of AGEs to their receptor might lead to production of free oxygen species 
and induce pro-inflammatory processes. Schwenger et al., using RAGE-deficient mice, suggested that 
T cells could be activated in response to binding a RAGE ligand197. This is in line with the 
observation that the binding to RAGE can also activate signalling pathways, including mitogen-
activated protein kinases198 and transcription factor NF-κB pathway194. 
 
Finally, the low pH of the PDFs used to prevent the degradation of PD fluids during sterilization 
process could be a source of an irritation. This hypothesis, however, remains without verification199. 
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Figure 7. The PD fluid itself is capable of releasing a wide range of pro-inflammatory cytokines and eventually 
leads to an inflammatory response. (A) The normal peritoneum in a non-PD patient and (B) the peritoneum on 
PD treatment. 
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The main goal of this thesis was to gain insights into the involvement of CD69 in peritoneal fibrosis 
by using CD69 deficient mice in an established peritoneal dialysis mouse model. 
 
In order to achieve this goal we had the following aims: 
 
1. To examine the in vivo contribution of CD69 in peritoneal fibroproliferative responses 
induced by dialysis fluid by studying the expression of inflammatory and fibrotic markers, 
measuring the peritoneal thickness and analyzing the Th1/Th2/Th17 and Treg responses in the 
peritoneal cavity. 
 
2. To analyze the role of CD69 in the regulation of the Th17/Tregs balance in experimental PD. 
 
3. To demonstrate that CD69 exerts its function within the lymphocyte compartment by 
generating chimeric mice.  
 
4. To confirm the involvement Th17 response in peritoneal fibrosis by blocking IL-17 in CD69-/- 
mice. 
 
5. To validate the involvement of CD69 in peritoneal fibrosis by blocking the CD69 molecule in 
WT mice. 
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1. Human sample analysis 
 
1.1. Samples 
 
Non-PD and PD patients biopsies were gathered from the Department of Pathology Unit (Hospital de 
la Princesa). Similarly peritoneal effluent cells were collected from the peritoneal dialysis unit, 
Nephrology Department (Hospital Universitario La Paz). Peritoneal effluent cells were obtained from 
two different randomized patients. One was a six-month ongoing PD patient with an episode of 
peritonitis and the other was a normal 6-month PD patient without episode of peritonitis (free-
infection). 
 
1.2. CD69 expression in human peritoneum 
 
1.2.1. CD69 expression in peritoneal effluent cells  
 
Cell suspensions obtained from peritoneal lavage from PD patients were stained with fluorochrome-
conjugated mouse-specific antibodies against CD3 (Miltenyi 130-094-965), CD4 (Miltenyi 130-091-
231), and CD69 (Table 8). Samples were analysed in a BD FACS Canto II (BD Biosciences) flow 
cytometer and further analyses were performed with FloJo software. 
 
 
 
	  
	  
	  
                                            
 
 
 
 
Table 4. PBS buffer (10X) components. 
 
2. Mice experiments 
 
2.1. Mice 
 
CD69-deficient mice were generated in the 129-Sv background as described14 and were backcrossed 
to C57BL/6 for more than 12 generations. CD69–/– and control wild type mice used for experiments 
were 8 to12 week-old females, and were either littermates or age-matched offspring of these 
littermates in the C57BL/6 background. Rag2-/-γc-/- double knockout were kindly provided by Dr. 
M.L. Toribio (Centro de Biología Molecular, CSIC, and Spain). All mice were maintained and used 
under pathogen–free conditions at the Animal Facility of CNIC (Centro de Investigaciones 
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Cardiovasculatres, Spain). All animal procedures were approved by the Ethics Committee of CNIC 
and Comunidad Autónoma de Madrid, and were conducted in accordance with institutional guidelines 
that comply with the National Institutes of Health’s Guide for the Care and Use of Laboratory 
Animals. 
 
2.2. Peritoneal exposure model  
 
2.2.1. Catheter installation	  
 
A customized vascular access port (ROP; Access Technologies, USA) was implanted into the mice. 
The catheters had 10 holes located within 1 cm of the tip to help the fluid exit and to prevent 
obstructions (Figure 8A). The animals were anaesthetized with intraperitoneal 100 mg/kg isofluoran. 
Afterwards, we performed an incision in the skin in the right flank of the animal. The skin was 
separated from the muscle layer below. Through another incision in this second layer, we introduced 
the end of the catheter into the peritoneal cavity (Figure 8B). The port was displaced at the 
subcutaneous space of the mouse's back (Figure 8C). 
 
2.2.2. Procedure 
 
During the first week post-surgery, 0.2 mL saline was instilled in order to prevent catheter trapping. 
Thereafter, during the experimental procedure, 2 mL standard PD fluid (PDF, lactate with 4.25% 
glucose; Fresenius Medical Care, Bad Homburg, Germany) or physiologic saline (Salina Fisiologica 
Grifols 0,9%, Cloruro de Sodio reference: 610667) was instilled daily for 40 days. This volume was 
chosen because it is almost equivalent to a single exchange in PD patients, relative to body weight, 
and does not affect mouse respiration. The state of the animals’ health was checked daily by a 
veterinary doctor, and mice presenting any sign of illness were excluded from the experiment. We 
used 4 groups of mice in the 1st part of the project. The control groups WT and CD69-/- had a catheter 
and received 2 ml of physiologic saline (n=10/group). The treated WT and CD69-/- groups received an 
instillation of 2 ml of PDF daily through the catheter (n=10/group). In order to study the mechanism 
by which CD69 receptor is involved in peritoneal fibrosis, we performed the comparison between WT 
and CD69-/- PDF treated groups respectively. The experiment was repeated at least two times. The 
experimental procedure was performed according to NIH guidelines for the care and use of laboratory 
animals. The experimental procedure was approved by the institutional ethics committee. The whole 
experimental procedure and treatment protocol is summarized in figure 10. 
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A                      B                          C 
 
 
 
 
 
 
 
Figure 8. Catheter installation and PDF instillation in mice. (A) The catheter contains 10 holes located within 1 
cm of the tip to help the fluid exit and to prevent obstructions. (B) The catheter installation surgical procedure 
consists of a small inquisition in the right flank, where the catheter is sutured. (C) At the end of the procedure, 
the catheter port is located in the back of the mouse in the subcutaneous space. 	  
2.3. Bone marrow chimeric mice 
10-12 week old CD69+/+ and CD69-/- females were lethally γ-irradiated with 2 doses of 6.5 Gy and 
transferred i.v. with a mixture of 4x106 BM cells from Rag2-/-γc-/- and CD69-/- or Rag2-/-γc-/- and WT 
cells in a proportion of 3:1 respectively. The Rag2-/- gamma c-double mutant mice are completely 
alymphoid (lack T-, B- and NK- subsets) which gives specificity to our assay: myeloid cell subset will 
belong to the Rag2-/- gamma c-double mutants whereas lymphocyte compartment will belong only to 
WT or CD69-/- donors (Figure 9).  Reconstitution of the immune system by the donors was analysed 6 
weeks after bone marrow transplant and reconstituted mice were subsequently analysed 40 days after 
PD treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Schematic representation of the generation of bone marrow chimeric mice. 
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2.4. IL-17 blocking experiments 
PDF-instilled CD69-/- mice were treated with a recombinant neutralizing antibody against IL-17A 
(eBioscience, affymetrix, reference: 16-7173) or its corresponding control (mouse IgG1K, isotype 
control Ab). Anti-IL-17A and IgG1-K antibodies (100µg / mouse) were instilled in the peritoneal 
cavity of the mice thought an installed catheter together with PDF solution every 5 days for a total 
period of 40 days.  
 
2.5. CD69 blocking experiments 
Murine Ab CD69-2.2 (IgG1-k), specific for mouse CD69, was generated as described19, 200, 201.  It was 
purified from concentrated supernatants obtained in an INTEGRA CL 350 flask (Integra Biosciences 
AG, Switzerland) using a protein G column (Pharmacia- Biotech, Uppsala, Sweden).  Purified mAb 
was dialyzed extensively against PBS, tested for endotoxin (levels were < 0.1 ng/ml) and stored at -20 
degrees. As a control  the murine IgG1 anti-human CD69 (mAb-2.8) purified in the same way was 
used. PDF-instilled WT mice were treated with a neutralizing antibody (mAb-2.2) against CD69 
(Materials and methods 2.5.1 section). CD69 neutralizing antibody can reduce dramatically the 
expression of CD69 in all compartments of the mouse. A dose of (100µg / mouse) was instilled in the 
peritoneal cavity through the catheter together with PDF every 5 days for a total of 40 days. As 
control group WT PDF-instilled mice were treated with the murine IgG1 anti-human CD69 (mAb-
2.8) (isotype control Ab). 
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Figure 10. Summary of the experimental procedure and the treatment methods followed throughout the whole 
project. 
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2.6. FACs analysis 
Cell suspensions obtained from peritoneal lavage and peritoneal membranes from PDF-treated and 
untreated mice were sequentially filtered through 70-µm (BD Falcon) and 40-µm (Miltenyi Biotec) 
cell strainers. Cells were stained with fluorochrome-conjugated mouse-specific antibodies against 
CD45.1, CD45.2, CD4, CD8α, B220, CD11b, Ly-6C, CD25, Gr-1, IFN-gamma, IL-4 and IL-17, 
purchased from BD Pharmingen and FoxP3 (eBiosciences). Before intracellular staining, cells were 
re-stimulated for 4 h with 50ng/ml PMA and 500ng/ml ionomycin in the presence of 1µg/ml 
Brefeldin A. Samples were analysed in a BD FACS Canto II (BD Biosciences) flow cytometer and 
further analyses were performed with FloJo software. 
 
2.7. Real-time quantitative (q) PCR 
cDNA for real-time quantitative PCR (qPCR) was generated from 0.5 µg of total RNA using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) in a 10 µl of final reaction volume. 
The qPCR reactions were performed in triplicate using 10µl of each cDNA 1/40 dilutions, 10 µM of 
each oligonucleotide and HOT FIREPol qPCR mix (Solis Biodyne) in a total volume of 8 µl in 
MicroAmp Optical384-well plates (Applied Biosystems). PCR reactions were carried out in an ABI 
PRISM7900HT (Applied Biosystems). The amount of amplified DNA was measured through the 
emission of light by the SYBR green dye, intercalating in synthesized double stranded DNA. All 
samples were measured in triplicates. SDS v2.2 software was used to analyze results. Specific 
amplification was controlled by melting-curve analysis. The data were exported, processed to 
Microsoft excel and analyzed by the comparative Ct Method (DDCt). X-fold change in mRNA 
expression was quantified relative to control WT samples from the same experiment.  β-actin mRNA 
was used as a housekeeping gene. The primers that were used in this study were as follows:  
 
 
Table 5. Sequences of oligonucleotides used in the experiments. 
Gene  Forward Sequence (5’ à  3’) Reverse Sequence (5’ à  3’) 
Collagen I CCAGAGTGGAACAGCGATTAC GCAGGCGAGATGGCTTATTT 
Fibronectin GCAAACCTATAGCTGAGAAGTC CAAGTACAGTCCACCATCATC 
IL-1β TGGTGTGTGACGTTCCATT CAGCACGAGGCTTTTTTGTTG 
IL-6 GAGGATACCACTCCCAACAGACC AAGTGCATCATCGTTGTTCATACA 
TGFβ GGAACTCTACCAGAAATATAGCAACAATTC TGTAATCCGTCTCCTTGGTTCAG 
β-actin AAGGAGATTACTTGCTCTGGCTCCTA ACTCATCGTACTCCTGCTTGCTGAT 
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2.8. Immunoblotting 
Proteins were denatured using standard loading buffer, containing 5% of β-mercaptoethanol (Table 6), 
for 10 minutes at 99°C. Polyacrylamide gel electrophoresis (PAGE) was performed according to a 
common procedure. Denatured protein samples, at volumes corresponding to equal protein amounts, 
were loaded into 12.5% polyacrylamide gel wells and proteins were separated in a running buffer 
(Table7) connected to a source of electrical field (120 V, for 2 hours, at RT). 
 
  Table 6. Loading buffer  (1X) components.               Table 7. Running buffer  (1X) components.      
           
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	   	   	   	   	   	      
 
Separated proteins were electro-blotted onto a nitrocellulose membrane using a transfer buffer (Table 
4). The membrane was later incubated with a blocking solution, containing 5% skimmed milk 
dissolved in a TBS buffer (Table 5) with 0.1% of Tween 20, at RT. The blocked membrane was 
incubated overnight with a primary antibody (Table 8) diluted in a blocking solution at 4°C. Protein 
expression was addressed using fluorescent secondary antibodies (Table 9) and LI-COR Odyssey 
infrared scanning. 
 
Table 8. List of primary antibodies used in the experiments. (*) WB - western blot (immunoblotting); IF-
immunofluorescence, (**) Rb - rabbit; Ms - mouse;  
 
Antibody Name Company and Reference No. Dilution Used * Specificity  
Phospho-Stat3 (D3A7) (Tyr705) Cell Signalling, #9145 1:1000 (WB) Rb 
Stat3 Santa Cruz Biotechnology, sc-482 1:1000 (WB) Rb 
β -actin Millipore, MAB2081 1:20000 (WB) Ms 
 CD69 (TP1/55.3.1) R& D Systems, MAB23591 1:50 (IF) Ms 
α -SMA 
 
 
 
Sigma A2547 1:50 (IF) Ms 
Cytokeratin Novocastra 5D3 1:50 (IF) 
Ms 
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Table 9. List of secondary antibodies used in the experiments. (*) WB - western blot (immunoblotting); IF - 
immunofluorescence. 
 
Antibody Name and Specificity Company and Reference No. Dilution Used * 
Alexa Fluor 680 Goat Anti-Rabbit Molecular Probes, A-21109 1:5000 (WB) 
Alexa Fluor555 Mouse IgG1Anti-Mouse Molecular Probes, Z-25005 1:500 (IF) 
Alexa Fluor 647 Donkey Anti-Rabbit Molecular Probes, A-31573 1:500 (IF) 
FITC Polyclonal Rabbit Anti-Mouse DakoF0313 1:50 (IF) 
 
 
2.9. FlowCytomix 
 
To determine the quantity of different cytokines and chemokines in the peritoneal effluents, the 
peritoneal cavity was washed with 2 ml of saline immediately after the mice were euthanatized. The 
solution was centrifuged and the supernatant was analyzed for cytokine and chemokine production 
using the FlowCytomix technique (Bender MedSystems GMbH). 
 
2.10. Trichrome Massons staining 
 
Parietal peritoneal biopsies were collected from the opposite side of the catheter installation. The 
biopsies were fixed in Bouin’s solution, embedded in paraffin, cut into 5 µm sections and stained with 
Trichrome Massons. The peritoneal membrane thickness was determined using a microscope (Leica 
CTR6000, with a Leica Microsystems LAS-AF6000). Microphotographs were obtained using an 
Olympus BX41® clinical microscope and an Olympus DP20® digital camera using cell Acquisition 
software. The peritoneal thickness of each mouse was calculated by the median of measurement taken 
every 50 µm from one extreme to the other of biopsy. The result was used to calculate the group 
thickness. 
 
2.11. Immunofluorescence 
 
Biopsies were frozen in OCT and cut into 5 µm sections. To block unspecific proteins the sections 
were incubated, for 1 hour at 37°C, in 20% of goat serum in 3% of bovine serum albumin (BSA) in 
distilled water. To identify mesothelial cells, we used mouse anti-cytokeratin (Table 8). Fibroblasts 
were stained with α-SMA antibody (Table 8). Both antibodies were diluted in blocking solution and 
then added onto the tissue sections that were placed in a humid chamber for an overnight incubation 
at 4°C. As secondary antibodies Alexa Fluor Zanon Fab fragments were used in each case (Table 9). 
Finally, the preparations were mounted with a 4,6-diamidino-2-phenylindole (DAPI) nuclear stain 
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(Vectashield; Vector Laboratories). Negative controls for immunofluorescent staining were conducted 
using 10% horse serum instead of primary antibody. Micrography was performed with a fluorescence 
microscope (Leica CTR6000, Leica Microsystems Heidelberg, Germany, with LAS-AF6000 
software) or with a confocal microscope (Leica TCS SPE with LAS-AF software, version 2.0.1 build 
2043). 
 
2.12. Statistical analysis 
 
Data were analyzed by paired or unpaired Student’s t-test, depending on the type of data, using 
GraphPad Prism 5.03. P values ≤ 0.05 were considered significant different. Results are means ± SD. 
Correlations were assessed using Spearman’s correlation tests (GraphPad Prism 5.03). 	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1. CD69 expression in T lymphocytes from PD patients 
 
In order to support the clinical relevance of our PD animal model using CD69-deficient mice, we first 
wanted to confirm the expression of CD69 in human samples of patients undergoing PD.  
 
Since CD69 is expressed in activated T cells, including lymphocytes in peripheral lymphoid tissues8, 
we collected cells from peritoneal effluents from two randomized patients and performed T cell 
stainings using specific CD3, CD4 and CD69 antibodies, according to the procedure described in 
Materials and Methods. Two samples were taken from a patient suffering from an episode of 
peritonitis (day 1 and one week later counting from the beginning of infection) and the other was 
collected from a 6-month PD patient free of infection.   
 
Analysing flow-cytometry results, we found that CD69 was highly expressed in CD3-positive T cells 
from both patients (Figure 11A, B). Interestingly, in the peritonitis patient CD69 was expressed on 
about 24% of CD3-positive cells at day 1 of the infection episode, and this fraction was even higher at 
day 7, reaching almost 50%. Similarly, the analysis of the second non-infected patient, treated for 6 
months with PD, showed that CD69 was also expressed in a big fraction of the CD3-positive T cells 
of the peritoneal cavity. The percentage of CD4+CD69+ cells was approximately a half of the 
CD3+CD69+ sub-population (Figure 11B), showing that half of CD69 expressing lymphocytes belong 
to the CD4 subset of peritoneal cells from PD patients. 
 
 
 
Figure 11. CD69 is expressed in peritoneal effluent cells of patients undergoing PD. Flow-cytometry analysis of 
CD3+ gated lymphocytes: (A) CD3+/CD69+ and (B) CD4+/CD69+ staining.	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2. CD69 in PDF-induced fibrosis in mice 
 
CD69-/- mice have been reported to be sensitive to exogenous stimuli and they produce an induced 
inflammatory response in different models. In order to evaluate the role of CD69 receptor in 
peritoneal fibrosis, we performed 3 independent in vivo experiments using WT and CD69-/- mice and 
PD protocol (as described in Materials and Methods). It has been demonstrated that WT mice, after 
exposure to PDF for at least 21 days, develop a remarkable fibrosis following inflammation compared 
to controls140, 202, 203. We treated mice for different periods of time (10, 20 and 40 days) with PD fluid 
and analysed the samples (peritoneal effluent cells and peritoneal membrane (PM) biopsies). 
  
The PD catheter implantation was followed by daily treatments with physiologic saline (control 
group) or with the standard PDF (lactate with 4.25% glucose; Fresenius Medical Care) at a total 
volume of 2 ml each time. This volume was chosen because it is almost equivalent to a single 
exchange in PD patients, relative to body weight, and does not affect mouse respiration. 
 
2.1. 10-day PDF treatment 
 
Following the 10-day exposure to PDF, we observed no increase of the PM thickness in either WT or 
CD69-/- mice, compared with saline-treated controls, using a specific Trichrome Massons staining of 
the paraffin-embedded sections (Figure 12A,B). Also the numbers of total cells (Figure 12C) and 
percentages of T cells, including Th17 cells (Figure 12D), from the peritoneal cavity, measured by 
flow-cytometry, were mostly similar in all untreated and treated mice. We only observed a decreased 
number of Treg (CD4+FoxP3+) cells in PDF-treated CD69-/- mice compared to all remaining groups, 
although this difference was statistically significant only between the treated groups (Figure 12E). It 
is known that during inflammation the number of Tregs is usually decreased. We hypothesised, 
therefore, that this decrease could be a sign of inflammation possibly starting at day 10 in PDF-
instilled CD69-/- mice. In addition, the levels of pro-inflammatory cytokines: IL-17, IL-6, IL-1β and 
TGFβ in peritoneal effluent protein remained unchanged independently of the treatment in both 
genotypes (data not shown).  	  
2.2.  20-day PDF treatment 
 
2.2.1. Fibrotic and cellular response 
 
In order to evaluate fibrotic response in both genotypes at longer times after initiation of the PDF 
treatment, we exposed WT and CD69-/- mice to PDF for 20 days. After mice sacrifice we performed 
Trichrome Massons staining to measure the peritoneal thickness (Figure 13A). 
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Figure 12. PDF treatment of WT and CD69-/- mice (10 days). (A) Representative pictures of PM stained with 
Trichrome Massons. Black arrows indicate PM. (B) Peritoneal membrane thickness. (C) Quantification of the 
total peritoneal cells in the peritoneal cavity. (D,E) Percentage of Th17 (D) and Treg (E) cells in the peritoneal 
cavity measured by flow-cytometry. Values in (B-E) are means ± SD (n≥5). *p<0.05 was considered 
statistically significant. Student t-test was used. 
 
 	  
Figure 13. PDF treatment of WT and CD69-/- mice (20 days). (A) Representative pictures of PM stained with 
Trichrome Massons. (B) Peritoneal membrane thickness. (C) Quantification of the total peritoneal cells in the 
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peritoneal cavity. Values in (B,C) are means ± SD (n≥5). p<0.05 was considered statistically significant. 
*p<0.05, **p<0.01. Student t-test was used. MCs: mesothelial cells. 
 
PDF-instilled WT mice presented only a small increase in fibrosis. However, we observed that PDF-
instilled CD69-/- mice developed a significant fibrotic response compared with tCD69-/- and WT 
controls and also with PDF-instilled WT group (Figure 13B). This demonstrates that instillation of 
PDF in CD69-/- mice induces morphological alterations in PM, coinciding with fibrotic changes 
observed in clinics in PD patients. Moreover, after the sacrifice of the mice, the peritoneal cavity was 
washed extensively in order to collect peritoneal cells. We found that PDF-instilled CD69-/- mice 
displayed a high number of total peritoneal cells in the peritoneal cavity compared both to a control 
group and to PDF-instilled WT mice. We suspected that this cell abundance was an indicator of an 
inflammatory response (Figure 13C). 	  
2.2.2. Inflammatory cells in the peritoneal cavity 
 
Inflammation is one of the adverse effects in patients under PD treatment and it can lead to the 
interruption of the therapy204. After we evaluated the thickening of the PM in both genotypes we 
wanted to further study inflammatory processes, such as monocyte and neutrophil accumulation in the 
peritoneal cavity in mice undergoing PD. 
 
 
 	  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Flow-cytometry analysis of (A,B) CD11b+Ly6G+ (monocytes), (A,C) CD11b+Ly6Ghigh (neutrophils) 
and (D) CD45+ cells in the peritoneal cavity of WT and CD69-/- mice treated or not with PDF for 20 days. 
Numbers in quadrants indicate percentages of cells. Values in (B-D) are means ± SD (n≥5). p<0.05 was 
considered statistically different. *p<0.05, **p<0.01. Student t-test was used. 
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Figure 15. Different (A) chemokines and (B) cytokines released in the peritoneal cavity after 20 days of the 
PDF treatment. Data are expressed as means ± SD (n≥5). p<0.05 was considered statistically significant. 
*p<0.05, **p<0.01. Student t-test was used. 
 
 
Using flow-cytometry analysis, we found that both monocytes (CD11b+Ly6G+) and neutrophils 
(CD11b+Ly6Ghigh) were increased in the PDF-instilled CD69-/- mice, whereas in PDF-instilled WT 
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mice we did not observe this induction (Figure 14A-C). Moreover, we found that CD69-/- mice treated 
with PDF displayed high numbers of infiltrating CD45+ cells (Figure 14D), which is probably due to 
the recruitment of inflammatory cells, including neutrophils and monocytes, to the peritoneal cavity. 
 
2.2.3. Pro-inflammatory cytokines and chemokines in the peritoneal cavity 
 
Pro-inflammatory chemokines and cytokines are molecules released during a sustained inflammatory 
response. In this regard, we wanted to examine their levels in the peritoneal effluents from mice of 
both genotypes after 20 days of PDF treatment. 
 
After the mice sacrifice we collected the peritoneal effluents and using the FlowCytomix technique 
(see Materials and Methods) we analysed a number of cytokines and chemokines (Figure 15). We 
found that chemokines GMCSF, MIP1α, MIP1β and RANTES were significantly up-regulated in the 
PDF-instilled CD69-/- group compared with control and were, in general, higher than treated WT 
mice, also in the case of MCP3, but not MCP1 (Figure 15A). Noteworthy, the above-mentioned 
chemokines are released mainly by macrophages and T cells when a sustained inflammation takes 
place. 
 
It has been described that inflammatory cytokines, such as IL-6, ΤΝF-α and IL-17 are highly 
expressed in the peritoneal cavity during PD140, 205. Since we found that the PDF-treated CD69-/- mice 
expressed significantly higher levels of IL-2, IL-6, ΤΝF-α and IL-17 compared to WT (Figure 15B), 
we concluded that this induced cytokine expression in the knockout mice contributes, at least in part, 
to the fibrosis of the PM and to immune cells accumulation in the cavity, previously described in 
sections 2.2.1 and 2.2.2 of Results. 
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2.2.4. T cells in the peritoneal effluents 
 
CD69 is involved in experimental and human inflammatory diseases and Th17 cells mediate many of 
these inflammatory responses41. We were interested, therefore, to analyse different Th cell 
populations from the peritoneal cavity of mice undergoing PD. We quantified the numbers of Th1, 
Th2, Th17 and Treg cells from peritoneal effluents, using flow-cytometry (Figure 16). 
 
 
 
Figure 16. The total numbers of (A) CD4+IL-17+ (Th17), (B) CD4+IFNγ+ (Th1), (C) CD4+IL-4+ (Th2) and (D) 
the percentage of CD4+FoXP3+ (Treg) cells collected from the peritoneal cavity of WT and CD69-/- mice treated 
or not with PDF for 20 days. (E) Ratio between Th17 and Tregs. Data are expressed as means ± SD (n=5). 
p<0.05 was considered statistically significant. **p<0.01. Student t-test was used. 
 
 
We observed that the PDF-instilled CD69-/- group presented elevated number of total Th17 (CD4+IL-
17+) cells compared with the PDF-instilled WT mice and control group (Figure 16A). However, we 
did not detect any significant differences for the remaining T cells between WT and CD69-/- PDF-
treated groups (Figure 16B-D). In addition and accordingly to these results, the ratio Th17 / Tregs in 
the peritoneal effluent from treated knockout mice was significantly higher than in WT (Figure 16F). 
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2.3. 40-day PDF treatment 
 
2.3.1. CD69 deficiency promotes fibrosis and increases peritoneal cells number 
 
Previously described results reveal that the CD69-/- mice are more prone to PM thickening (fibrosis) 
than WT during 20-day peritoneal dialysis (Figure 13A-C). In order to further confirm our data and to 
address the influence of the CD69 deficiency on the PDF-treatment outcome in mice during a longer 
exposure to PD, we performed the similar procedure by treating mice for 40 days with saline 
(controls) or PD fluid.  
 
 
Figure 17. PDF treatment of WT and CD69-/- mice (40 days). (A) Trichrome Massons staining of PM sections 
in WT and CD69-/- mice treated or not with PDF. Representative pictures are shown. Arrows shows the 
peritoneal mesothelial cells layer in controls and solid lines show thickness of PM in the PDF treated groups. 
Representative photos from necropsies with PM images are represented below for each group. (B) Peritoneal 
membrane thickness. (C) Quantification of the total peritoneal cells in the peritoneal cavity. In (B,C) data are 
means ± SD (n≥9). P values <0.05 were considered statistically significant: *p<0.05, ***p<0.001. Student t-test 
was used. (D) Correlation between total number of cells and PM thickness (Spearman regression, p<0.0001; r2 
=0.694; Ν=36).  
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The fibrotic response was checked using Trichrome Massons staining of PM sections from WT and 
CD69-/- mice. We observed that after 40 days of PDF treatment both genotypes showed an increased 
thickness of PM comparing with control (Figure 17A,B). Of note, CD69-deficient mice were 
characterised by a more pronounced fibrotic response than PDF-instilled WT mice and the difference 
between the two groups was statistically significant (Figure 17B). The thickened PM in treated mice 
observed in tissue sections coincides with a phenotypical image of the peritoneum during necropsy, 
manifested by reduced transparency of the membrane and its whitening corresponding to the fibrotic 
process (photograph inserts in Figure 17A).  
 
Furthermore, total cells from the peritoneal cavity, extensively washed with physiologic saline, were 
higher in number upon PDF treatment and this increase was more induced in CD69-/- mice comparing 
with WT (Figure 17C). Moreover, we found a very strong correlation between the thickening of the 
PM and the total number of cells found in the peritoneal cavity with a p value <0.0001 (Figure 17D). 
 
 
2.3.2. CD69 deficiency leads to an increase in expression of fibrotic markers. 
 
One of the primary changes observed in biopsies from patients undergoing PD is the thickening of the 
peritoneum, which is due to the deposition of collagen and fibronectin. The main sources of collagen 
in fibrotic tissues are fibroblasts. Fibronectin is a glycoprotein of the extracellular matrix and is a very 
important protein for the differentiation and embryonic development. Both have been previously 
described as key markers for the evaluation of a fibrotic response during PD140, 206, 207. 
 
In order to evaluate a possible involvement of the CD69 deficiency on the expression of these two 
markers during PM fibrosis, we measured the mRNA levels of the corresponding genes from total 
RNA extracted from PM biopsies from controls and PDF-treated WT and CD69-/- mice. Using RT-
qPCR we found that both collagen and fibronectin were up-regulated after PDF at the mRNA level, 
but only in CD69-/- mice; this induction was absent in WT (Figure 18). 
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Figure 18. Quantitative RT-PCR of collagen I and fibronectin mRNA in total RNA from PM tissue from WT 
and CD69-/- mice treated or not with PDF for 40 days. Results were normalised to β-actin mRNA and 
represented in arbitrary units as means ± SEM. One corresponds to a WT control (n=3). p<0.05 was considered 
statistically significant. *p<0.05, ***p<0.001. Student t-test was used. 
 
 
2.3.3. CD69 protects against mesothelial to mesenchymal transition  
 
One of the typical changes that take place during PD is the conversion of mesothelial cells into 
mesenchymal cells displaying acquired fibroblastic phenotype185. This process is one of the main 
etiologic factors of the functional decline of the peritoneum during PD. 
 
In our CD69-/- model we found that the deficiency of CD69 induces the MMT process. In order to 
visualise mesothelial cells that acquired a specific fibroblastic phenotype after exposure to PDF, we 
stained PM biopsies with antibodies against cytokeratin (mesothelial marker) and α-smooth muscle 
actin (α-SMA) (fibroblastic marker) as shown in Figure 19. We observed that PDF-instilled CD69-/- 
mice presented significantly higher number of fibroblasts (red cells) compared to PDF-instilled WT 
mice and controls (Figure 19A). Moreover, PDF-instilled CD69-/- mice displayed an increased number 
of double positive cells for cytokeratin and α-SMA cells, which corresponded to mesothelial cell 
acquiring fibroblastic character (Figure 19A-B).  
 
In addition, the immunofluorescent analysis revealed a very strong correlation between the double 
positive (cytokeratin/α-SMA-positive) cells and thickening of the peritoneum (Figure 19C). In 
conclusion, under these conditions the CD69 deficiency exacerbates the mesothelial to mesenchymal 
transition after exposure to PDF. 
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Figure 19. (A) Immunofluorescent microscopy analysis of parietal peritoneal tissue sections stained for α-SMA 
(red) and cytokeratin (green) with a 4,6-diamidino-2-phenylindole (DAPI) counterstaining. (B) Number of 
double positive cells for α-SMA and cytokeratin as per field. 10 randomized calculations per mouse were 
performed. Data are means ± SD (n=9). p<0.05 were considered statistically significant. *p<0.05, ***p<0.001. 
Student t-test was used. (C) Correlation between cytokeratin/α-SMA-positive cells of peritoneal tissue and 
thickness of the PM (Spearman regression, P<0.0001; r2 =0.811; Ν=36). 
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2.3.4. CD69 deficiency promotes expression of Th17-related cytokines  
 
The inflammatory response is orchestrated by a wide range of growth factors and cytokines and their 
altered expression may have a major impact on immune response. TGFβ and IL-6 are important for 
the differentiation of Th17 cells55-57. Their presence creates an environment that forces T cells to 
differentiate towards Th17 lineage, what is mediated by the activation of RoR(γ)t transcription factor. 
Moreover, Martín et al. (2011) reported that in activated T cells deficient in CD69, the lack of CD69 
promotes induction of RoR(γ)t transcription factor and, subsequently, Th17 differentiation208. 
 
We analysed whether the enhanced fibrotic response in PDF-instilled CD69-/- mice could be 
influenced by altered cytokine expression. We checked the expression of a panel of pro-inflammatory 
cytokines at the protein level in peritoneal effluents, by FlowCytomix, and at the mRNA level in 
peritoneal membrane, by quantitative RT-PCR. 
 
IL-17, IFN-γ and IL-4 are the most representative cytokines released from Th17, Th1 and Th2 cells, 
respectively. At 40 days after the PDF treatment initiation, there was an increase of IL-17 in the 
effluent of PD fluid-treated CD69-/- mice, whereas the remaining cytokines (INF-γ and IL-4) did not 
show significant differences among groups (Figures 20A-C).  
 
The analysis of cytokines implicated in Th17 differentiation revealed that only TGFβ increased 
significantly in PDF-treated CD69-/- mice, whereas IL-6 did not show differences among groups and 
IL-1β was increased in the effluent of both control and PDF-treated CD69-/- mice (Figure 20D,F,H). In 
contrast, when the expression of TGFβ, IL-6 and IL-1β was analysed at the mRNA level in the 
peritoneal tissue, all three cytokine-encoding transcripts increased significantly in PDF-treated     
CD69-/- mice (Figure 20E,G,I). Taken together, these data indicate that TGFβ, but not IL-6 or IL-1β, 
was mostly locally produced and that local Th17 differentiation was mainly TGF-β-dependent. 
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Figure 20. Quantitative analyses of cytokines from WT and CD69-/- mice after 40-day treatment with PDF. (A-
C) Bars represent the concentration of IL-17, IFN-γ and IL-4. (D, F, H) The quantification of pro-inflammatory 
cytokines TGFβ, IL-6 and IL-1β in the peritoneal effluents by FlowCytomix (n≥8). (E,G,I) mRNA expression 
levels of TGFβ, IL-6 and IL-1β assessed by quantitative RT-PCR (n≥3). Data are means ± SD. p<0.05 was 
considered statistically significant, using Student t-test. *p<0.05, **p<0.01, ***p<0.001. 
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2.3.5. CD69-/- mice display increased numbers of CD4- and CD8-positive T cells 
 
In order to further characterise cell populations infiltrating the peritoneal cavity in response to PDF-
induced inflammation and to check a possible influence of the CD69 deficiency on this process, we 
calculated the CD4- and CD8-positive cells in the peritoneal cavity, using flow-cytometry. The results 
are presented in Figure 21. 
 
 
 
Figure 21. Flow-cytometry analysis of CD8+ and CD4+ lymphocytes recruited in the peritoneal cavity of WT 
and CD69-/- mice treated or not with PDF for 40 days. (A) Density blots with corresponding percentages of the 
CD4/CD8 positive cells. (B, C) Total numbers of CD8+ (B) and CD4+ (C) cells in the peritoneal effluents. Data 
are means ± SD (n≥6). p<0.05 was considered statistically significant. *p<0.05, **p<0.01, ***p<0.001. Student 
t-test was used. 
 
PDF treatment resulted in an increase of both T cell populations in the two genotypes compared with 
saline-treated mice (Figure 21). However, in comparison with WT, CD69-/- mice presented higher 
total numbers of CD4 and CD8-positive cells after PDF (Figure 21B,C), indicating their involvement 
in PDF-provoked peritoneal inflammation. 
 
 
2.3.6. CD69 deficiency induces the Th17 response but not the Th1 and Th2 responses 
 
As mentioned above, CD69-/- mice exposed to PDF were characterised by a pronounced induction of 
IL-17 expression in the effluents. Flow-cytometry results in Figure 22 are in line with these data; we 
have observed that peritoneal cavity of PDF-treated knockout mice was highly enriched by CD4+IL-
17+ (Th17) cells compared to control and also to PDF-challenged WT mice (Figure 22A,B). However, 
A     C     B 
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and with one exception, we did not observe any differences in Th1 and Th2 numbers between groups 
(Figure 22C,D). We only found that CD4+IFNγ+ (Th1) cells were increased in the CD69-/- PDF-
treated mice compared with control (Figure 22C). 
 
Furthermore, Th17 cells were strongly correlated with peritoneal thickness (Figure 22E), suggesting 
that Th17 cells play an important role in the development of peritoneal fibrosis and that this role is 
regulated by CD69. In conclusion, our results unequivocally demonstrate that CD69 exerts a 
regulatory role in Th17 differentiation in the PD model. 
 
 	  	  
Figure 22. (A) Density plot of flow-cytometry analysis of CD4+IL-17+ (Th17) and CD4+IFNγ+ (Th1) cells. 
Numbers in quadrants indicate percentages of corresponding cells. (B-D) Total numbers of CD4+IL-17+ (Th17), 
CD4+ IFNγ+ (Th1) and CD4+ IL-4+ (Th2) cells collected from the peritoneal cavity. Data are means ± SD (n≥6). 
p<0.05 was considered statistically significant. *p<0.05, **p<0.01. Student t-test was used. (E) Correlation 
between Th17 cell numbers and thickness of PM (Spearman regression, P<0.0001; r2 =0.777; Ν=33).  
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2.3.7. CD69 deficiency impairs the balance between Th17 and Treg  
 
Using the PD model we wanted to check a possible importance of the presence or absence of CD69 in 
regulation of Treg cells during the exposure to PDF. 
 
Peritoneal cells were collected from control and treated WT and CD69-/- mice and stained with 
specific antibodies for CD4 and FoxP3 markers, and analysed by flow-cytometry. In both genotypes 
the PDF treatment resulted in a significantly decreased percentage of Tregs compared to 
corresponding controls in the levels for each condition were similar regardless of the CD69 status 
(Figure 23A,B).  
 
The elevated number of Th17 cells (Figure 22B) in PDF-treated mice, much higher particularly in the 
knockout mice explains the differences in an observed misbalance between Th17 and Tregs between 
the two genotypes (Figure 23C). Specifically, in PDF-treated CD69-/- mice the Th17/Treg ratio was 
higher than in WT; the difference was, however, insignificant between the two genotypes (Figure 
23C). This result coincides with the data obtained from 20-day protocol in which we observed a 
significantly higher Th17/Tregs ratio in treated CD69-/- mice compared with WT (Figure 16E). 
 
 	  
Figure 23. (A) Density plot analysis of flow-cytometry of CD4+ gated FoxP3+ (Treg) cells in WT and CD69-/- 
mice treated or not with PDF. Numbers in quadrants indicate a percentage of cells corresponding to the 
quadrant. (B) Percentage of regulatory T cells in the peritoneal cavity. (C) The ratio between the total numbers 
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of Th17 and regulatory T cells present in the peritoneal cavity after 40 days of treatment with PDF or saline 
(control). Results are means ± SD (n≥6). Differences were considered statistically significant for p values <0.05: 
*p<0.05, **p<0.01. Student t-test analysis was performed. 
 
 
2.3.8. CD69 deficiency promotes the recruitment of myeloid cells into the peritoneal cavity 
 
PDF treatment in its acute phase is characterized by inflammatory cells infiltration into the peritoneal 
cavity, including monocytes and neutrophils. These cells are the primary signs of an inflammatory 
response. 
 
To further demonstrate the role of CD69 in the inflammation after 40 days of exposure to PDF we 
stained peritoneal cells from WT and CD69-/- mice with Ly6G and CD11b specific antibodies and 
analysed them by flow-cytometry. We found a significantly higher number of monocytes and 
neutrophils in PDF-instilled CD69-/- mice compared to PDF-instilled WT and controls (Figure 24A-
C). These results indicate that the deficiency of CD69 favours the accumulation of monocytes and 
neutrophils in the peritoneal cavity during PD and contributes to peritoneal inflammation mediated by 
these cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. (A) Density plot of flow-cytometry analysis of CD11b+ and Ly6G+ cells. In each quadrant the upper 
square represent neutrophils and the bottom quadrant - monocytes. Numbers in quadrants indicate percentages 
of the corresponding cells. (B,C) Total numbers of CD11b+Ly6G+ (monocytes) (B) and CD11b+Ly6Ghigh 
(neutrophils) (C) in the peritoneal cavity. Data are as means ± SD (n≥6). Values between indicated groups were 
considered significantly different for p<0.05 (Student t-test): *p<0.05, **p<0.01, ***p<0.001. 
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We were also interested to check infiltrating inflammatory cells present in the PM. We found that in 
PDF-instilled CD69-/- mice both monocytes and neutrophils were elevated compared to CD69-/- 
control group. Moreover the number of CD4 and CD8 infiltrating cells were increased in the PDF-
instilled CD69-/- mice compared to controls. However, PDF-instilled CD69-/- mice presented a 
diminished number of B cells compared to CD69-/- control and PDF-instilled WT group. This was 
probably due to the fact that during an inflammation B cells migrate to the lymph nodes (Table 10). 
 
Table 10. Composition of immune cells in the PM in WT and CD69-/- mice after 40 days of treatment. *p<0.05, 
**p<0.01, ***p<0.001, #p<0.001 WT-PDF vs. CD69-/-PDF. 
 
 	  
3. CD69 in lymphoid cell-mediated fibrosis in bone marrow chimeric mice 	  	  
3.1. Chimeric mice generation 
 
To ascertain the role of CD69 expression in the lymphocyte compartment, we performed chimera 
experiments. In order to analyse the contribution of innate immunity to the enhanced fibrotic response 
observed in our previous experiments in PDF-instilled CD69-/- mice, irradiated WT (CD69+/+) mice 
received BM transplant of Rag2γ-/-CD69-/- (KO) BM cells and, in parallel, CD69-/- (KO) mice were 
reconstituted with Rag2γ-/-CD69+/+ (WT) BM cells. Additionally, we added two control groups: WT 
recipients were reconstituted with Rag2γ-/-CD69+/+ (WT) cells and CD69-/- mice reconstituted with 
CD69-/-Rag2-/- (KO) cells. All groups were treated equally with PDF for 40 days, according to the 
same protocol described before. 
 
Prior to the PD protocol initiation, eight weeks after BM transplantation, we analysed B and T cell 
development in the chimeric mice. Using flow-cytometry we observed that the percentages of CD4+, 
CD8+, NKs, and B cells remained constant among all groups (Figure 25A-E). Moreover, we evaluated 
the percentages of CD69-expressing cells within CD4+ T cell population in peripheral blood from 
chimeric mice; we confirmed a successful reconstitution (Figure 25F). 
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Figure 25. CD69+/+ (WT) and CD69-/- (KO) recipients were lethally irradiated and reconstituted with a mix of 
BM cells from WT or KO cells from donors as described in Material and Methods. (A) Flow-cytometry density 
plot analysis of corresponding markers in peripheral blood cells (PBL) from chimeric mice. (B-E) Percentages 
of (B) CD4, (C) B (D) NKs and (E) CD8 cells in the four chimeric groups. (Right part of panel A and panel F) 
Scatter plot analysis and a corresponding quantification of CD4+CD69+ cells in PBL in the four chimeric 
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groups. For determination of CD69 expression T cells from peripheral blood were activated with 50 ng/ml PMA 
and 500 ng/ml ionomycin for 4 h. Data are expressed as means ± SD (n≥6). P values <0.05 were considered 
statistically significant: *** p <0.001. Student t-test was used. 	  	  
3.2. Transfer of Rag2γ-/-CD69-/-  cells into WT increases peritoneal fibrosis in response to PD 
 
We addressed the involvement of CD69-expressing lymphocytes in PDF-induced fibrosis using the 
reconstituted chimeric mice. We first analysed the thickening of the peritoneal membrane in the four 
groups using Trichrome Massons staining and measuring the PM thickness as shown in Figure 26.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Peritoneal thickness in reconstituted mice subjected to a 40-day exposure to PDF. (A) Trichrome 
Massons staining of parietal peritoneal tissue. Representative pictures are shown. (B) Thickness of  PM. Data 
are means ± SD (n≥4). P values <0.05 were considered statistically significant using Student t-test: **p<0.01. 
 
We found that WT mice reconstituted with donor KO cells and treated with PDF presented an 
exacerbated fibrotic response compared with PDF-treated WT mice reconstituted donor WT cells. It 
was manifested by an increased deposition of extracellular matrix (fibrosis) observed by light 
microscopy as appearance of bluish elements in PM. Contrarily, CD69-/- mice reconstituted with 
donor WT cells and subjected to PDF treatment presented a significantly lower fibrosis compared to 
PDF-treated CD69-/- mice reconstituted with KO cells. These data unequivocally demonstrate that 
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CD69 exerts an important panel in peritoneal fibrosis during PD and that the effect observed comes 
from the lymphoid and most probably not from the myeloid compartment. 
 	  
3.3. Transfer of Rag2γ-/-CD69-/- cells into WT induces the Th17, but not Th1-/Th2-responses 
 
Taking into consideration that PDF-treated CD69-/- mice presented an increased Th17 response, we 
wanted to check if this response would be reproduced in the CD69+/+ group reconstituted with Rag2-/-
CD69-/- cells and treated with PDF for 40 days. Once the PD protocol was completed, we stained 
peritoneal cells with markers specific to Th17, Th1 and Th2 cells and analysed them by flow-
cytometry (Figure 27). The WT mice transplanted with KO cells  displayed an increased fraction of 
Th17 cells compared with the WT/WT mice. Accordingly, CD69-/- mice reconstituted with WT cells 
presented a significantly reduced percentage of Th17 cells comparing with KO/KO. In the case of Th1 
and Th2 responses and in contrast to Th17 response, we did not detect clear differences within 
recipient groups reconstituted with either CD69-positive or –negative donor cells. 
 
 	  
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Analysis of flow-cytometry data of Th17 (CD4+IL-17+), Th1 (CD4+IFNγ+) and Th2 (CD4+IL-4+) 
cells from the peritoneal cavity. Bars represent percentages of indicated cells in each chimeric group. Data are 
means ± SD (n≥7). p<0.05 was considered statistically significant using Student t-test: * p <0.05, ** p <0.01. 	  
Remarkably our data demonstrate that Rag2γ-/-CD69-/- cells transferred to WT BM recipients lead to 
an induced fibrotic response and Th17 differentiation in the peritoneal cavity under these conditions. 
These results support the notion that CD69 acts as a regulator of Th17 response in our PD model and 
that its activity is highly associated with lymphocytes during PD. 
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4. Implication of IL-17 in PDF-induced fibrosis in the CD69-deficient mice 
 
The classical view of the immune system has been changed by the discovery of a novel T cell subset, 
Th17 cells. IL-17A, produced by these cells, participates in immune-mediated kidney pathologies, 
such as glomerulonephritis, and more recently it has been linked with renal injury in an experimental 
model. Moreover, biopsies from long- and short-term PD patients, immunostained with specific 
antibodies, were IL-17A-positive predominantly in inflammatory areas, but not in the healthy 
peritoneum. Besides, chronic exposure to dialysis fluids resulted in a peritoneal Th17 response, 
including elevated IL-17A gene and protein production, submesothelial cell infiltration of IL-17A-
expressing cells, and up-regulation of Th17 differentiation factors and cytokines. This was the first 
result highlighting IL-17 implication in peritoneal inflammation and fibrosis140. 
 
We already demonstrated that PDF-instilled CD69-/- mice presented exacerbated peritoneal fibrosis 
after 40 days of treatment. However, PDF-instilled WT group was characterised by smaller level of 
fibrosis, compared with CD69-/- PDF treated mice. We wanted to check whether IL-17 is involved in 
this pronounced response and if blocking the IL-17 pathway in the PDF-instilled CD69-/- mice would 
rescue the increased fibrotic response. 
  
In order to evaluate a possible contribution of IL-17 in peritoneal fibrosis in CD69-/- mice, PDF-
instilled CD69-/- mice were treated with a neutralizing antibody (Ab) against IL-17 or its 
corresponding isotype control Ab. Both groups were equally treated for 40 days with PD fluid. 
 
4.1. Blocking of IL-17 results in a diminished fibrotic response 
 
After the sacrifice of mice we checked the fibrotic response in both PDF-instilled CD69-/- group 
treated or not with the anti-IL-17 neutralizing Ab. Surprisingly, we saw that while treatment of  
CD69-/- mice with PDF plus an isotype control presented an exacerbated fibrotic response, while this  
response was completely abolished in the CD69-/- group, simultaneously instilled with PDF and 
neutralizing anti-IL-17 Ab (Figure 28A,B). In addition, we observed a significant reduction in the 
total number of peritoneal cells in CD69-/- mice treated with PDF enriched with IL-17 Ab (Figure 
28D). This was probably due to the fact that blocking of IL-17 pathway decreased the inflammatory 
response associated among others with infiltration of immune cells into the peritoneal cavity.  
 
Moreover, we measured the levels of detectable IL-17 in the peritoneal effluents by FlowCytomix. 
We found that mice treated with anti-IL-17 Ab did not contain detectable IL-17 (Figure 28C). Also, 
total peritoneal cells, decreased in the Ab-treated mice compared with control, were significantly 
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correlated with peritoneal thickness (Figure 28E), which is in agreement with the fact that high 
number of peritoneal cells is linked with the development of peritoneal fibrosis in PDF-treated mice. 
 
 
Figure 28. PDF-instilled CD69-/- mice were treated regularly with a neutralizing anti-IL-17 Ab or its 
corresponding control antibody (100 µg/mouse every 5 days via peritoneal catheter), starting with PDF 
treatment. (A) Trichrome Massons-stained sections show that administration of a neutralizing Ab against IL-17 
dramatically decreased the thickness of the peritoneal membrane, compared with CD69-/- mice treated with the 
isotype control plus PDF. Representative pictures are shown. (B) Statistical analysis of the PM thickness in both 
groups (n≥5). Horizontal lines are means. Error bars represent SD. ***p<0.001. (C) FlowCytomix 
quantification of IL-17 in the peritoneal effluents at the end of the experiment. IL-17 is not detected (n.d) in the 
PDF-treated mice administered with the neutralizing anti-IL-17 Ab (n≥5). (D) Total numbers of peritoneal cells 
recovered from both groups after the end of experiment (n≥4). In (C,D) data are means ± SD. P values <0.05 
were considered statistically significant using Student t-test: **p<0.01. (E) Correlation between total cell 
numbers and thickness of PM (Spearman regression, P<0.01; r2 =0.772; Ν=10). 
 
These results confirm that IL-17 pathway is important for peritoneal fibrosis development is the PD 
model. 
IL-17 
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4.2. Blocking of IL-17 results in a decreased Th17 response 
 
We then were interested to check the CD4+IL-17+ (Th1), CD4+IFNγ+ (Th2) and CD4+IL-4+ (Th2) 
responses in the peritoneal effluent cells. 
 
 
 
Figure 29. PDF-instilled CD69-/- mice were treated with a neutralizing Ab against IL-17 or control isotype 
antibody (100 µg/mouse every 5 days, via the peritoneal catheter). (A) Density plot of flow-cytometry analysis 
of IL-4+, IL-17+ and IFN-γ+ cells. (B-E) Percentages of CD4+IL-17+ (Th17) (B), CD4+IFNγ+ (Th1) (C), CD4+IL-
4+ (Th2) (D) and CD4+FoXP3+ (Treg) cells (E) in the peritoneal effluents from both groups. (F) Th17/Treg 
ratio. In (B-F) data are expressed as means ± SD (n≥8). Values with p<0.05 were considered statistically 
different using Student t-test: **p<0.01, N.S – not significant. 
 
After 40 days of the combined PDF/anti-IL-17 Ab treatment we analysed by flow-cytometry the 
above T cell peritoneal populations. We found that Th17 cells were dramatically decreased in the 
PDF-instilled CD69-/- group that was enriched with the neutralizing antibody against IL-17 (Figure 
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29A,B). However, we did not observe any significant differences between the two groups regarding 
Th1 and Th2 responses (Figure 29A,C,D). The decreased percentage of Th17 cells is in accordance 
with our previous observation showing no IL-17 detection in the peritoneal effluents in the same 
group (Figure 28C). No difference was observed in the number of Tregs between the groups after 
blockade with the anti-IL-17Ab. 
 
These data confirm that blocking of IL-17 activity in PDF-treated knockout mice rescues the Th17 
cell increase in the peritoneal cavity undergoing fibrosis. 
 
4.3. Effect of IL-17 blockade on the number of monocytes and neutrophils 
 
After analyzing the T subsets we wanted to check a possible changes in numbers of monocytes and 
neutrophils in the total peritoneal cells in response to IL-17 blocking in dialysed mice. We collected 
the effluents and performed flow-cytometry of Ly6G- and CD11b-stained cells. The summary of the 
analysis is shown in Figure 30. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Percentages of (A) CD11b+Ly6G+ (monocytes) and (B) CD11b+Ly6Ghigh (neutrophils) in the 
peritoneal effluents from indicated groups. Data are expressed as means ± SD (n≥8). Values with p<0.05 were 
considered statistically different using Student t-test *p<0.05. 
 
Interestingly, we found that PDF-instilled CD69-/- mice that were administered with the anti-IL-17 
Ab, presented significantly lower amounts of CD11b+Ly6G+ (monocytes) cells compared to non-IL-
17-treated group (Figure 30A). However, although CD11b+Ly6Ghigh (neutrophils) showed a tendency 
to decrease, they failed to reach significant difference compared to control (Figure 30B). This finding 
suggests that blocking of IL-17 pathway in PDF-instilled CD69-/- mice reduces the production of 
inflammatory cells such as monocytes and neutrophils. 
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5. Blockade of CD69 exacerbates the response to PDF and reproduces the CD69-/- 
phenotype 
 
It has been previously described that CD69 targeting by antibodies affects the course of many 
diseases in experimental mouse models. For example treatment with anti-CD69 (mAb-2.2) reduced 
the severity of collagen induced arthritis (CIA) by partially depleting CD69-expressing T cells200. 
Another study showed that the administration of the same mAb-2.2 in vivo down-regulates CD69 and 
leads to an effective lack of CD69 expression on the cell membrane, without any depletory effect209. 
 
To further confirm the importance of the CD69 receptor in vivo in attenuation of the PDF-induced 
peritoneal fibrosis and inflammation we used anti-CD69 mAb (mAb-2.2, mouse IgG1) in order to 
block CD69 expression in mice subjected to PD. We hypothesised that targeting CD69 receptor in 
PDF-instilled WT mice would reproduce the fibrotic, Th17 and Treg responses observed in PDF-
instilled CD69-/- mice. We used WT mice treated with a combination of PDF and either isotype 
control Ab (mAb-2.8, control group) or a neutralizing Ab against CD69 (mAb-2.2). Both groups were 
treated for 40 days under the same conditions. 
 
	  
Figure 31. WT mice were treated with PDF combined with anti-CD69 mAb or control mAb (100 µg/mouse 
every 5 days) for 40 days. (A) Representative pictures of Trichrome Massons-stained sections. Administration 
of anti-CD69 mAb significantly increased the matrix deposition and the thickness of peritoneal membrane, 
compared to isotype control. (B) Analysis of the PM thickening in the two groups. Data are expressed as means 
± SD (n≥5). Values with p<0.05 were considered significantly different using Student t-test. *p<0.05. 
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5.1. Fibrosis 
 
To determine whether the mAb-2.2-induced down-regulation of the CD69 expression enhanced the 
peritoneal fibrosis in PDF-treated WT mice, PM biopsies were analysed according to the previous 
protocol (Figure 31). Observation of the Trichrome Massons stainings of PM sections by light 
microscopy and measurements of the membrane thickness revealed that mAb-2.2 (anti-CD69 Ab)-
treated mice displayed an increased fibrosis compared with mAb-2.8 (control)-treated mice. 
Administration of anti-CD69 mAb and CD69 expression blockade in PDF-instilled WT mice 
reproduced, therefore, the exacerbated fibrotic response, previously observed in PDF-treated CD69-/- 
mice at day 40. Our data coincide with other published animal model, in which the CD69-/- phenotype 
was restored in WT mice by mAb-2.8-mediated in vivo CD69 down-regulation200.  
 
5.2. Th17/Treg balance 
 
To gain an insight into a possible mechanism by which CD69 regulates peritoneal fibrosis through the 
regulation of the Th17 and Treg responses, we wanted to analyse the Th17, Th1, Th2 and Treg 
responses in the peritoneal cavity of WT mice treated with PDF supplemented with mAb-2.2 or mAb-
2.8. 
 
Flow-cytometry analysis of peritoneal cells from these mice showed an induced Th17 response in 
PDF-instilled WT treated with anti-CD69 antibody compared with control (Figure 32A,B). This 
finding suggests that blocking CD69 during PD results in an augmented Th17 response, similarly to 
the PDF treatment of CD69-/- mice as observed before. Accordingly to these previous results, we did 
not observe changes in the Th1/Th2 responses in the two groups, either (Figure 32C,D). In contrast, 
the Treg population was significantly decreased after CD69 blocking (Figure 32E,F). Expectedly, a 
high induction of the ratio between Th17 and Tregs was also observed in WT mice with down-
regulated CD69 expression (Figure 32G). 
 
Summarizing, our data present that the exogenous CD69 down-regulation in mice under the PDF 
treatment is a potent pro-fibrotic factor, which also causes an impaired balance between Th17 and 
Treg cells in the peritoneal cavity. 
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Figure 32. (A-D) Flow cytometry density plots (A,E) and data analysis of (B) Th17 (CD4+IL-17+), (C) Th1 
(CD4+IFNγ+), (D) Th2 (CD4+IL-4+) and (E,F) Treg (CD4+FoxP3+) cells in the peritoneal effluents. (B-D,F) The 
percentage of Th17, Th1, Th2 and Tregs cells is shown. (G) The ratio between the percentage of Th17 and 
Tregs is shown. Data are expressed as means ± SD (n≥5). Values with p<0.05 were considered statistically 
different using Student t-test: *p<0.05. 
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5.3. Analysis of neutrophils and monocytes in the peritoneal cavity 
 
Monocytes and neutrophils are two populations that are mainly elevated during exposure of the 
peritoneum to PDF. Using specific stainings and flow-cytometry analysis we found that 
CD11b+Ly6G+ (monocytes) and CD11b+Ly6Ghigh (neutrophils) were augmented in the PDF-instilled 
WT groups administered with the mAb-2.2 compared to control (mAb-2.8) group (Figure 33). Thus, 
the blockade of CD69 in PDF-instilled mice induced an inflammatory phenotype similarly to the 
effect observed in the treated CD69-/- mice (Figure 24). Therefore, CD69 is important for the 
preservation of the immune response during PD. 	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: (A) Density plot analysis of (B) CD11b+Ly6G+ (monocytes) and (C) CD11b+Ly6Ghigh (neutrophils) 
in the peritoneal effluents. (B) Graphs represent percentages of indicated cell population in the peritoneal cavity. 
Data are means ± SD (n≥5). Values with *p<0.05 were considered statistically different, using Student t-test. 
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DISCUSSION 
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Published data highlight the importance of CD69 in regulating inflammatory responses19-21. For 
instance, CD69 deficiency resulted in an enhanced inflammation in murine models of cardiac 
disease21, thereby revealing a protective anti-inflammatory role of CD69 in these pathologies. 
 
Recent data also suggest that Th17 and Treg cells, present in the peritoneal cavity during peritoneal 
dialysis (PD), are major factors influencing the outcome of the peritoneal functions. Local stimulation 
of Th17, during the dialysis, is mediated by exogenous and endogenous signals (Figure 34). The 
exogenous factors include bacteria and their derivatives and provoke episodes of peritonitis by 
entering into the peritoneal cavity through the PD-catheter or via intestinal translocation210. On the 
other hand, endogenous factors, such as AGEs211 might be involved in the IL-17 induction by 
activating pro-inflammatory cytokines IL-6 and/or TGFβ, which are both promoters of Th17 
differentiation. Thus, an induced Th17 activity during PD could be associated with a poor prognosis 
and peritoneal damage. Moreover, it has been demonstrated that effluents of the peritoneal cavity in 
PD patients, suffering from peritonitis episodes, contained increased levels of IL-17210. Although IL-
17-dependent peritoneal membrane (PM) deterioration, manifested by mesothelial to mesenchymal 
transition (MMT), has not been demonstrated, IL-17 is capable of inducing MMT in bronchial 
cells212. We therefore hypothesised that IL-17 could contribute to the MMT induction in PM as well. 
 
 
 
Figure 34. Mechanism of the Th17/Treg balance in the peritoneal cavity during PD.  
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It has been demonstrated that Treg cells are strongly connected with immune tolerance, as patients 
suffering from end-stage renal diseases had a suppressed immunity, partially due to impaired 
regulation of Tregs213. However, at present there is little information regarding the role of Treg cells 
in the peritoneal cavity during PD. There are only two studies on the functions of Treg cells in 
peritoneal damage, in which the authors demonstrated their protective role141, 203. 
 
In this thesis, we have defined, for the first time, a novel role of CD69 as a negative regulator of the 
fibrotic and inflammatory response during PD through the modulation of proportions of Th17 and 
Treg cells in the peritoneal cavity. We have established this connection by subjecting CD69-/- mice to 
the PD procedure. We have also shown that a possible mechanism of this regulation is through the 
balance between Th17 and Treg cells, both contributing to peritoneal fibrosis. 
 
Previous studies had reported that WT mice exposed to PD fluid (PDF) for 21 days presented induced 
fibrotic response in the peritoneal membrane when compared with controls203. However, we did not 
observe this phenomenon at day 20 and our WT mice displayed a phenotype rather similar to that 
observed in control group. This discrepancy could be explained, at least in part, by imperfect animal 
maintenance conditions and lower expertness level in the mentioned work and/or due to different 
origins of the mice used in both studies. Interestingly and contrary to the WT mice, the severity of 
PDF-induced peritoneal fibrosis was remarkably induced in CD69-/- mice at this time point. 
Interestingly, an application of a longer procedure, by exposing both genotypes to PDF for 40 days, 
resulted in peritoneal fibrosis induction in each group, however to a different extent. Specifically, the 
loss of CD69 was again associated with a fibrosis exacerbation (Figure 35A). 
 
In order to verify a possible role of CD69 in bone marrow (BM)-derived cells on the induction of the 
fibrotic response we performed experiments with chimeric mice using Rag2γ-/-, WT (CD69+/+) and 
CD69-/- mice. The transfers of Rag2γ-/-/CD69-/- BM into WT and Rag2γ-/-/CD69+/+ BM into CD69-/- 
were performed to check if the fibrotic effect observed in the PDF-treated CD69-/- mice was due to the 
lymphoid compartment. After a 40-day treatment of the reconstituted chimeras with PDF, the WT 
immunized recipients, with Rag2γ-/-CD69-/- BM cells, displayed severe peritoneal fibrosis, mimicking 
the phenotype previously observed in PDF-treated CD69-/- mice (Figure 35B). In contrast, the transfer 
of Rag2γ-/-/CD69+/+ BM cells into CD69-/- mice and their exposure to PDF led to a significantly lower 
response when compared with the fibrosis of the CD69-/- control chimeras. These data indicate that 
CD69 exerts its regulatory functions during the PD-dependent peritoneal damage through the 
lymphoid cells. 
 
In order to further confirm the protective role of CD69 during PD we used neutralizing anti-CD69 
murine antibody (mAb)-2.2, to down-regulate the in vivo function of the protein200 without 
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CD69-expressing cells in WT mice. The effect of this antibody consistently mimics the CD69-/- 
phenotype in different experimental models, as shown, for example, antitumour immune response19, 
CIA200 and in acute arthritis induced by anti-collagen type-II antibodies22. In each study the blockade 
of CD69 in WT mice with mAb-2.2 increased the severity of pro-inflammatory responses. In this 
regard, our results clearly showed that the down-regulation of CD69 in PDF-instilled WT mice 
increases severity and progression of peritoneal damage. We showed that combined instillation of WT 
mice with PDF and mAb-2.2 for 40 days provoked an exacerbated fibrosis comparing to no-mAb-2.2 
controls and similar to the one observed in the PDF-instilled CD69-/- mice (Figure 35C). Taken 
together, our data indicate that the enhanced fibrotic response present in CD69-deficient mice is 
specifically result of the lack of CD69 expression. Noteworthy, this experiment establishes CD69 as a 
possible factor involved in the peritoneal fibrosis in PD patients.  
 
 
Figure 35. Effects of different in vivo procedures on the severity of the PDF-induced peritoneal fibrosis: (A) 
Induced fibrosis in CD69-/- mice treated with PDF alone. (B) Induced fibrosis of CD69+/+ immunized bone 
marrow recipients injected with a mixture of Rag2γ-/-CD69-/- cells and treated with PDF alone. (C) Induced 
fibrosis in WT mice administered with a combination of PDF and anti-CD69 antibody. 
 
The involvement of IL-17 in the pathogenesis of peritoneal fibrosis has recently been documented140. 
The authors demonstrated that IL-17 was over-expressed in peritoneal biopsies from both mice and 
human. This was the first study to demonstrate that IL-17 participates in typical fibrotic changes 
occurring in peritoneal membrane during long-term PD (induced expression of fibronectin, α-SMA 
and FSP-1). The same study revealed besides that intraperitoneal injection of exogenous IL-17 into 
PDF-treated WT mice increased the damage to the peritoneum comparing with non-IL-17 PDF-
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treated mice. Accordingly, an intraperitoneal injection with a neutralizing antibody against IL-17 into 
PDF-treated mice attenuated the phenotypical changes in the PM , including the progress of peritoneal 
fibrosis. 	  
It has been described that CD69 deficient mice exacerbate Th17 and Th2 responses in a model of 
allergic asthma and contact hypersensitivity20. In this study the authors also showed that inflammatory 
response in these mice was accompanied by elevated IL-17 levels. It is therefore conceivable that the 
increased Th17 response might be responsible, at least in part, for the increased inflammation in 
CD69-/- mice.  
 
Our study proposes that exposure of the peritoneal membrane of CD69-/- mice to PDF for 20 and 40 
days induces a local Th17 inflammatory response, which is significantly elevated compared to WT 
PDF-treated group at both time points. We demonstrated the importance of IL-17 in peritoneal 
dialysis. This is the first study showing that CD69 controls peritoneal fibrosis by regulating the IL-17 
expression in the peritoneal cavity during PD. This conclusion was gathered from four different 
independent experiments including chimeric mice generation and in vivo neutralization of IL-17 and 
CD69. PDF exposure of CD69-/- mice probably creates an ideal environment for T cells without CD69 
receptor or with impaired CD69 function, to differentiate into Th17 and thereby to initiate an 
inflammatory process. Therefore, the increased inflammatory response observed after 40 days in the 
CD69 deficient mice was partially due to the high levels of the pro-inflammatory IL-17 cytokine 
found in the peritoneal effluents, which was one of the most abundant cytokine found in the peritoneal 
cavity.  
 
Apart from CD4+ lymphocytes, including Th17, IL-17 is also released by other cells, such as CD8+ T 
cells214, γδ T cells215, natural killer216, dendritic cells217 and, under special circumstances, by mast 
cells218, as shown in chronic rheumatoid arthritis and in experimental models of renal damage77. It has 
been described that IL-17 acts synergistically with IL-1β inducing a strong pro-inflammatory 
response219. In our study IL-1β level was increased too, therefore it is possible that it has a prominent 
role in inflammation (or at least in its induction) together with the IL-17, both driving peritoneal 
inflammation and fibrosis. In contrast to WT, the deficiency of CD69 in PDF-treated mice led to a 
significant increase of TGFβ in peritoneal effluents measured at the protein level; it was not observed 
in the case of IL-6. We hypothesize, however, that the constant, relatively highly expressed IL-6 
could be involved in a complex mechanism by which TGFβ, IL-6 and IL-1β all coordinate the 
induction of IL-17 and induce inflammation and fibrosis. In addition, it is described that IL-17 itself 
can induce fibroblastic, epithelial and endothelial cells to release IL-6 and IL-8220, 221. In unresolved 
chronic inflammation IL-6 signaling itself might drive to peritoneal fibrosis222 and therefore this could 
be another mechanism by which IL-17 directly activates fibroblasts to produce IL-6 and guide to 
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fibrosis. Moreover, when fibroblasts were cultured in the presence of human IL-17, they could sustain 
the proliferation of CD34 hematopoietic progenitors and their preferential maturation into neutrophils. 
These observations suggest that IL-17 might constitute an early initiation of T cell-dependent 
inflammatory response220. 
 
 
 
Figure 36. Immunoblotting of phosphorylated Stat3, total Stat3 and α−SMA in protein lysates of PM tissue 
from WT and CD69-/- mice treated or not with PDF for 40 days. β-Actin was used as loading control.  
 
IL-17 is the most representative cytokine released from Th17 response during immune responses223.  
CD69 has been described as an unexpected regulator of Th17 activity208. It has been shown that the 
absence of CD69 receptor in the T cell membrane fails to phosphorylate Stat5 transcription factor 
(negative regulator of Th17 differentiation) and subsequently Stat3 is phosphorylated which is a 
positive regulator of Th17 response. Thus, RoR(γ)t transcription factor is activated and the fate of 
Th17 differentiation begins224. In our study when CD69 deficient mice were treated with PDF, we 
observed a significant increase of total Stat3 protein measured by immunoblotting, in lysates of 
peritoneum (Figure 36). The induced phosphorylation of Stat3 in the PDF-treated CD69-/- mice, 
compared with WT, was not significant and could be due to basal level of Stat3 activation, higher in 
Stat3-abundant samples (Figure 36). Supposing that Stat3 in the peritoneum is overexpressed in 
among others T cells, the partial induction of Stat3 could suggest, at least to some extent, its 
contribution to the T cell differentiation into Th17. 
 
So far there has been little information regarding the role of Treg cells in the peritoneal cavity during 
PD. There are only two studies focusing on the function of Treg cells on peritoneal damage141, 203. Our 
study, for the first time, describes the regulatory role of CD69 in the balance between Th17 and Tregs 
in the peritoneal cavity during experimental PD and how this balance may affect the outcome of PD. 
We found that the 20– or 40–day treatment of WT and CD69-/- mice with PD fluid gave rise to similar 
percentages of Treg cells in both groups. In contrast, we observed a higher ratio between total Th17 
and Treg cells in CD69-/- mice compared to WT group.  
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Figure 37. Regulatory role of CD69 in peritoneal fibrosis through the regulation of Th17 and Treg cells in the 
peritoneal cavity of CD69-/- mice during PD 
 
This result identified and established the first mechanistic link between CD69 and peritoneal fibrosis. 
Th17 and Treg cells seem to be the major players in peritoneal fibrosis. Conversion of CD4+FoxP3+ 
Tregs into Th17 cells with arthritogenic properties establishes a new in vivo pathological importance 
of Tregs conversion to Th17 cells225. Although CD69 deficiency diminishes the production of Tregs in 
the peritoneal cavity upon PDF exposure, it is possible that a fraction of Th17 cells comes from the 
conversion of Tregs into Th17. Thus the fate of Tregs might be a critical determinant of self-tolerance 
versus autoimmunity (Figure 37).  
 
The described mechanistic role of CD69-dependent regulation of peritoneal fibrosis was confirmed by 
bonne marrow (BM) transplantation. The transfer of Rag2γ-/-CD69-/- cells into WT BM recipients, 
followed by PD procedure, reproduced the effect of the increased Th17 response, as observed in 
CD69-/- mice treated with PDF. In contrast, CD69 deficient mice, reconstituted with Rag2γ-/-CD69+/+ 
BM cells, displayed a decreased percentage of Th17 cells in the peritoneal cavity. Moreover, 
accordingly to our previous data, the severity of the induced Th17 response was associated with 
increased peritoneal fibrosis (Figure 35B) and was consistent with the role of Th17/Treg balance in 
this pathology. 
 
We also evaluated the expression of key cytokines involved in Th17 and Treg differentiation. The 
differentiation of Th cell subsets is driven by cytokines and regulated by specific transcription factors. 
IL-6 promotes Th17 differentiation, whereas Th1/Th2 cytokines inhibit this process49, 226, 227. TGFβ 
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participates in Th17 differentiation by inhibiting Th1/Th2 activation226. We found that the levels of 
TGFβ and IL-6 were up-regulated in the PM of PDF-instilled CD69 deficient mice; it is in accordance 
with the fact that Th17 differentiation requires the co-operation of TGFβ and IL-6 cytokines55, 57. 
However, the hallmark Th1/Th2-related cytokines (IFNγ and IL-4) remained unchanged (Figure 37).  
 
Moreover, the blockade of IL-17 with a neutralizing antibody in CD69-/- mice undergoing PDF 
treatment, according to the procedure previously described in WT mice140, led to diminished 
peritoneal fibrosis (preservation of PM) and reduced inflammatory responses, manifested by lower 
Th17, monocytes and neutrophils (Figure 38). This confirms the already published data pointing to 
IL-17 as an important regulator of peritoneal fibrosis and inflammation140.  
 
 
 
Figure 38. Schematic representation of the phenomena occurred after blockade of Th17 response in CD69-/- 
mice. 
 
Last but not least, our results with the anti-CD69 mAb-2.2 demonstrate that the enhanced Th17 and 
reduced Treg responses present in CD69 deficient mice is a result of the loss of CD69 functions. 
When we blocked CD69 receptor in WT mice and subjected them to PD, we reproduced the increased 
Th17 response and decreased Treg response that we had observed in PDF-instilled CD69-/- mice 
(Figure 39). 
 
It has been described that mesothelial to mesenchymal transition (MMT) is one of the factors 
triggering peritoneal fibrosis122, 185. Many inflammatory mediators such as for example TNF-α, IL-1β 
and TGFβ  have a role in peritoneal fibrosis by stimulating resident fibroblasts proliferation and ECM 
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component deposition228. They also induce MMT, turning mesothelial cells  (MCs) of the membrane 
into fibroblasts whose number increases185. MCs that acquire fibroblastic properties during MMT are 
characterized by the expression of α-SMA and cytokeratin markers. Fibroblasts, which can be 
detected by immunofluorescence as α-SMA-positive cells, have a capacity to synthesize ECM, 
growth factors, and cytokines, thus participating in typical inflammatory responses and fibrosis181. 
CD69-/- mice presented a significantly increased number of these cells in the peritoneum after 
exposure to PDF for 40 days. As expected there was a strong correlation between the thickness of PM 
from treated CD69-/- mice and the number of double positive (α-SMA+Cyt+) fibroblasts. This indicates 
a unique role of CD69 in the peritoneal deterioration. Taken together, these results indicate that the 
inflammation/MMT axis drives the fibrotic process of the PM induced by the PD fluid exposure 
(Figure 37). 
 
 
 
Figure 39. Schematic representation of the phenomena occurred after blockade of CD69 receptor in WT mice. 
 
Moreover, immunoblotting of protein lysates of PM from untreated and PDF-treated mice with an α-
SMA antibody revealed that this protein is more expressed in CD69 knockouts than in WT mice 
exposed to PD (Figure 36). Since CD69 deficiency exacerbates fibrosis and increases Th17 
differentiation and MMT, it is possible that MMT is a part of this complex mechanism by which 
CD69 controls peritoneal fibrosis. Moreover, locally produced IL-17 could also activate mesothelial 
cells, which express the IL-17 receptor229, to release pro-inflammatory factors, contributing to the 
recruitment of leukocytes into the damaged peritoneum. It is tempting to speculate that one proposed 
mechanism by which CD69 regulates fibrosis through MMT process could be that IL-17 itself induces 
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the MCs to convert into fibroblasts, subsequently producing ECM components and contributing to 
peritoneal fibrosis. 
 
 
 
Figure 40. General scheme summarizing the possible regulatory role of CD69 and all the main possible 
pathways implicated in peritoneal fibrosis. I. Absence of CD69 induce the expression of Th17 cells and 
therefore release IL-17 which together with IL-6 and IL-1β may activate mesothelial cells to produce collagen 
and contribute to fibrosis. II) CD69 deficiency induces MMT and therefore forming fibroblasts and promoting 
collagen deposition. III) IL-17 produced from Th17 cells may interact with the IL-17 receptor located in 
mesothelial cells which give rise to collagen-secreting fibroblasts. 
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Inflammation is mediated, at least in part, by monocytes and neutrophils. Unresolved recurrent 
inflammation may contribute to fibrosis. In this study we show that CD69 deficient mice presented 
increased numbers of monocytes and neutrophils after a 20- and 40-day treatment. When we blocked 
IL-17 we significantly diminished the percentage of these cells. Similarly, by down-regulating CD69 
expression in WT mice we observed higher percentage of these populations in the peritoneal cavity. 
Taken together, monocytes and neutrophils could be also involved in the chronic inflammation 
driving peritoneal fibrosis. 
 
Concluding remarks 
 
Our study supports a novel role for the leukocyte activation receptor CD69 as a brake on the 
progression and severity of peritoneal damage and development of peritoneal fibrosis. We found that 
the genetic ablation of CD69 affects the outcome of experimental PD by regulating the balance 
between Th17 and Treg cells. These findings are of great importance because they provide a cellular 
and molecular basis for the development of novel specific therapies targeting peritoneal fibrosis 
through the regulation of Th17 and Treg responses. For example, the results from phase II clinical 
trials, in which patients with psoriasis were treated with specific antibodies targeting IL-17A or its 
receptor, proved their beneficial effect in humans230. 
 
In addition, our study paves the way to investigations into whether defects in CD69 expression or 
function influence the initiation and progression of peritoneal fibrosis in dialyzing PD patients. The 
recent discovery of the ligand of CD69 receptor (galectin-1) in DCs231 is a quite promising tool 
regarding its regulation of CD69 expression during PD. This ligand-receptor pair may represent in the 
future a novel regulatory pathway for the control of peritoneal fibrosis during PD. 
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1. CD69 has a modulatory role in peritoneal inflammation and fibrosis as shown by CD69-
dependent negative regulation of immune and fibrotic responses during PD. 
 
2. CD69 deficiency promotes exacerbated Th17 response and decreased the Treg response, leading 
to an increase of the ratio between the Th17 and Treg cells, whereas Th1 and Th2 responses 
remain almost unchanged. 
 
3. CD69 limits peritoneal fibrosis by modulating the mesothelial to mesenchymal transition.  
 
4. The induced fibrotic response in WT mice after bone marrow transplantation with Rag2γ-/-CD69-
/- BM cells demonstrates that CD69 exerts its function within the lymphocyte compartment. 
 
5. Blocking IL-17 in CD69-deficient mice abolishes peritoneal fibrosis.  	  
6. Blockade of CD69 in PD fluid-treated WT mice mimics the effect in treated CD69-/- mice 
demonstrated by the induced fibrosis and Th17 response and the decreased Treg response. 
 
7. These results point to possible new approaches for the therapy of peritoneal fibrosis by: (a) 
activating the early-leukocyte receptor CD69 in the human peritoneal cavity and (b) targeting the 
Th17/Treg-axis by decreasing Th17 response and/or increasing Treg response. 
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1. CD69 tiene un papel modulador en la inflamación peritoneal y la fibrosis del peritoneo asociado a 
una regulación negativa de la respuesta inmune y fibrótica durante la DP dependiente de CD69. 
 
2. La auscencia de CD69 promueve una respuesta Th17 exacerbada y una reducción de la respuesta 
Treg, lo que lleva al aumento de la proporción entre las células Th17 y Treg, mientras que las 
respuestas Th1 y Th2 se mantienen inalteradas. 
 
3. CD69 limita la fibrosis peritoneal mediante la modulación de la transición mesotelio 
mesenquimal. 
 
4. El invremento de la respuesta fibrótica en los ratones silvestres, tras el trasplante de médula ósea 
con células Rag2γ-/-CD69-/- demuestra que CD69 ejerce su efecto de la población de linfocitos. 
 
5. El bloqueo de IL-17 en los ratones deficientes para CD69 disminuye la fibrosis peritoneal. 
 
6. El bloqueo de CD69 en los ratones silvestres tratados con el fluido DP imita el efecto observado 
en los ratones CD69-/- bajo el mismo tratamiento, demonstrando una fibrosis inducida, una 
activacion de la respuesta Th17 y una disminuida respuesta Treg. 
 
7. Estos resultados sugieren nuevas dianas para el tratamiento de la fibrosis peritoneal humana a 
traves de: (a) la activación temprana del receptor CD69 en la cavidad peritoneal y (b) la 
regulación del equilibrio Treg/Th17 reduciendo la respuesta Th17 y/o aumentando la respuesta 
Treg. 
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